Effects of prenatal small-quantity lipid-based nutrient supplements on pregnancy, birth and infant outcomes: a systematic review and meta-analysis of individual participant data from randomized controlled trials in low- and middle-income countries

Kathryn G. Dewey, K. Ryan Wessells, Charles D. Arnold, Seth Adu-Afarwuah, Benjamin F. Arnold, Per Ashorn, Ulla Ashorn, Ana Garcés, Lieven Huybregts, Nancy F. Krebs, Anna Lartey, Jef L. Leroy, Kenneth Maleta, Susana L. Matias, Sophie E. Moore, Malay K. Mridha, Harriet Okronipa, Christine P. Stewart

Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA, USA (KGD, KRW, CDA, CPS)

Department of Nutrition and Food Science, University of Ghana, Legon, Accra, Ghana (SAA, AL)

Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA (BFA)

Center for Child, Adolescent and Maternal Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland (PA, UA)

Department of Paediatrics, Tampere University Hospital, Tampere, Finland (PA)

Proyecto Salud y Nutrición, Jhpiego, Guatemala City, Guatemala (AG)

Poverty, Health, and Nutrition Division, International Food Policy Research Institute, Washington, DC, USA (LH, JL)

Section of Nutrition, Department of Pediatrics, University of Colorado School of Medicine, Denver, CO, USA (NFK)

Department of Nutrition and Dietetics, School of Global and Public Health, Kamuzu University of Health Sciences, Blantyre, Malawi (KM)

Department of Nutritional Sciences and Toxicology, University of California, Berkeley,

Berkeley, CA, USA (SLM)

Department of Women & Children's Health, King's College London, London, UK and MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia (SEM)

Center for Non-communicable Diseases and Nutrition, BRAC James P Grant School of Public Health, Bangladesh (MKM)

Department of Nutritional Sciences, Oklahoma State University, Stillwater, OK, USA (HO)

Corresponding Author: Kathryn G. Dewey, Department of Nutrition, University of California, One Shields Ave., Davis, CA 95616; 530 752 0851; kgdewey@ucdavis.edu

Sources of Support: Bill & Melinda Gates Foundation OPP49817. The funder had no role in the design, implementation, analysis or interpretation of the data.

Short running head: Effects of prenatal SQ-LNS

Abbreviations: BEP, balanced energy protein; BMIZ, body mass index-for-age z-score; EFA, essential fatty acids; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCGAZ, head circumference-for-gestational age z-score; HCZ, head circumference-for-age z-score; IFA, iron and folic acid supplement; IPD, individual participant data; IRB, institutional review board; LAZ, length-for-age z-score; LBW, low birth weight; LMIC, low-

and middle-income countries; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; LNS, lipid-based nutrient supplements; LQ-LNS, large-quantity lipid-based nutrient supplements; MD, mean difference; MMS, multiple micronutrient supplement; MQ-LNS, medium-quantity lipid-based nutrient supplements; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference z-score; PR, prevalence ratio; RCT, randomized controlled trial; RR, relative risk; SAP, statistical analysis plan; SGA, small-for-gestational age; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplements; SVN, small vulnerable newborn; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score; WLZ, weight-for-length z-score.

Registry and registry number for systematic reviews or meta-analyses: Registered at www.crd.york.ac.uk/PROSPERO as CRD42021283391 on 11 April 2021.

Data described in the manuscript, code book, and analytic code will not be made available because they are compiled from 4 different trials, and access is under the control of the investigators of each of those trials.

Dr. Nancy Krebs is on the Editorial Board of the American Journal of Clinical Nutrition and played no role in the Journal's evaluation of the manuscript.

# 1 Abstract

2	Background: Undernutrition during pregnancy increases the risk of giving birth to a small
3	vulnerable newborn. Small-quantity lipid-based nutrient supplements (SQ-LNS) contain both
4	macro- and micronutrients and can help prevent nutritional deficiencies during pregnancy and
5	lactation.
6	Objectives: We examined effects of SQ-LNS provided to pregnant women, compared to a) iron
7	and folic acid or standard of care (IFA/SOC) or b) multiple micronutrient supplements (MMS),
8	and identified characteristics that modified effects of SQ-LNS on birth outcomes.
9	Methods: We conducted a 2-stage meta-analysis of individual participant data from 4
10	randomized controlled trials of SQ-LNS provided to pregnant women ( $n = 5,273$ ). We generated
11	study-specific and subgroup estimates of SQ-LNS compared with IFA/SOC or MMS and pooled
12	the estimates. In sensitivity analyses, we examined whether results differed depending on
13	methods for gestational age dating, birth anthropometry, or study design.
14	Results: SQ-LNS (vs IFA/SOC) increased birth weight (mean difference: +49g; 95% CI: 26,
15	71g), duration of gestation (+0.12 wk; 95% CI: 0.01, 0.24 wk), and all birth anthropometric z-
16	scores (+0.10-0.13 SD); it reduced risk of low birthweight by 11%, newborn stunting by 17%,
17	newborn wasting by 11%, and small head size by 11%. Only 2 trials compared SQ-LNS and
18	MMS; birth outcomes did not differ except for a marginal increase in head circumference for
19	gestational age (+0.11; 95% CI: -0.01, 0.23). Effect estimates for SQ-LNS vs IFA/SOC were
20	greater among female infants and among women with body mass index $< 20 \text{ kg/m}^2$ ,
21	inflammation, malaria, or household food insecurity. Effect estimates for SQ-LNS vs MMS were
22	greater among female infants, first-born infants, and women < 25 y.

- 23 Conclusions: SQ-LNS had positive impacts on multiple outcomes compared to IFA/SOC, but
- 24 further research directly comparing SQ-LNS and MMS is needed. Targeting SQ-LNS to
- vulnerable subgroups may be worth considering. Analysis registered at
- 26 www.crd.york.ac.uk/PROSPERO (CRD42021283391).
- 27 Keywords: Maternal nutrition, low birthweight, preterm birth, fetal growth restriction, balanced
- 28 energy protein supplementation, antenatal interventions, infant wasting, infant stunting

29

## 30 Introduction

31 Undernutrition is prevalent among women of reproductive age globally, with an estimated 1.2 billion deficient in one or more micronutrients (1), 571 million (30%) with anemia (2-4), and 170 32 33 million ( $\sim 10\%$ ) being underweight (3, 4). As a result, many women and girls enter pregnancy with nutritional deficits. The risk of undernutrition during pregnancy is exacerbated by the 34 35 elevated nutrient needs to support gestation, particularly in low- and middle-income countries (LMICs) where diets are often inadequate in multiple nutrients (5). This situation contributes to 36 poor maternal health and the risk of giving birth to a small vulnerable newborn (SVN), an 37 38 umbrella term that encompasses small-for-gestational age (SGA), preterm birth, and low birthweight (LBW) (6). In 2020, 26.2% of all livebirths globally were SVNs, with 16.3% SGA, 39 8.8% preterm, and 1.1% both SGA and preterm (7). Although poor nutrition is not the only cause 40 of these outcomes (8), interventions to improve maternal nutrition, such as multiple 41 micronutrient supplements (MMS) and balanced energy-protein supplementation (BEP) for 42 undernourished mothers, should be considered critical elements of antenatal care packages aimed 43 at reducing SVN births (9). 44 Lipid-based nutrient supplements (LNS) provide multiple micronutrients embedded in a food 45 base that also provides energy, protein and fat. LNS for pregnant women are a type of BEP, as 46 they meet the criterion that protein contributes < 25% of the energy content (10). The intended 47 daily ration of LNS can be small- medium- or large-quantity (SQ-, MQ- or LQ-LNS) (11). 48 Maternal SQ-LNS was designed to fill nutrient gaps during pregnancy and the first 6 mo 49 postpartum with a daily ration of only 20 g (118 kcal/d) (11), which minimizes cost and potential 50 51 displacement of home-prepared foods. SQ-LNS is not primarily designed to fill energy gaps, as

such gaps can be filled by more affordable local foods (11). SQ-LNS provides several key

nutrients not provided by iron and folic acid (IFA) supplements or MMS, including essential 53 fatty acids (EFAs) as well as calcium, magnesium, potassium, and phosphorus (11). This 54 combination of macro- and micro-nutrients addresses multiple potential nutritional deficiencies 55 and thus can reduce maternal undernutrition. Maternal SQ-LNS is currently being distributed by 56 USAID in selected food aid programs (12), but its use is not yet widespread. 57 58 A previous meta-analysis of maternal LNS (13) demonstrated that LNS given during pregnancy, 59 compared to IFA, had positive effects on birth weight, length, duration of gestation, SGA, and 60 newborn stunting. That meta-analysis included 3 trials, all of which used SQ-LNS. In a separate 61 comparison of LNS vs MMS that also included 3 trials (2 SQ-LNS, 1 MQ-LNS), there were no significant differences in birth outcomes (13). More recently, Hunter et al. (14) conducted a 62 meta-analysis of maternal LNS vs MMS that included 4 trials (2 SQ-LNS, 1 MQ-LNS, 1 LQ-63 LNS); they found a significant reduction in LBW but not preterm birth or SGA. The authors of 64 these previous meta-analyses did not have individual participant data (IPD) and thus were not 65 able to examine individual-level effect modification. 66 Effect modification analysis can provide important insights regarding the potential for 67 participants to benefit from an intervention, as well as their potential to respond (15). These 2 68 concepts reflect different attributes, with potential to benefit most likely related to greater deficits 69

at baseline, and potential to respond related to lack of constraints on exhibiting an improvement 70 in the outcome due to factors such as infection or inflammation. In some cases, individuals with

greater potential to benefit may also have a lower potential to respond, which can limit the 72

71

beneficial impact of an intervention. Identification of subgroups of pregnant women with the 73

74 greatest potential to benefit from or respond to LNS can help inform decisions regarding

targeting. We conducted an IPD meta-analysis of randomized controlled trials (RCTs) of SQ-75

7

LNS provided to pregnant women that had 2 objectives: 1) to compare overall effects of SQLNS with provision of a) IFA or standard of care (IFA/SOC) or b) MMS, and 2) examine
potential effect modifiers of the impact of SQ-LNS (as compared to either IFA/SOC or MMS) on
birth outcomes.

80

## 81 Methods

82 The protocol for this systematic review and IPD meta-analysis was prospectively registered on

83 PROSPERO (CRD42021283391) (16). The statistical analysis plan (SAP) is available on Open

84 Science Framework (<u>https://osf.io/nj5f9/</u>) (17) and was posted prior to analysis. The protocol was

reviewed by the institutional review board (IRB) of the University of California, Davis and

86 determined to be exempt from IRB approval given that protocols for each individual trial had

87 been previously approved by their respective ethical committees.

88

89 Inclusion and exclusion criteria for this IPD meta-analysis

90 We included prospective randomized controlled trials of maternal SQ-LNS that met the

91 following study-level inclusion criteria: 1) trial was conducted in a low- or middle-income

92 country (18), 2) maternal SQ-LNS (~125 kcal/d) was provided for at least part of pregnancy to

93 intervention group participants, 3) comparison group(s) received iron and folic acid (IFA),

94 multiple micronutrient supplements (MMS) (defined below) or standard of care (SOC), 4) trial

95 reported at least one outcome of interest (defined below), and 5) trial used an individual or

96 cluster randomized design in which the same participants were measured at baseline and endline

97 (longitudinal follow-up) or different participants were measured at baseline and endline

98	(repeated cross-sectional data collection). Trials were excluded if: 1) severe or moderate
99	malnutrition was an inclusion criterion for pregnant women to be eligible to participate, 2) study
100	was conducted with sick or hospitalized populations, 3) the only available comparison group
101	received other types of non-LNS maternal food supplementation, or 4) SQ-LNS provision was
102	combined with an additional nutrition-specific intervention within a single arm (e.g. SQ-LNS $+$
103	food rations vs. control), and there was no appropriate comparison group that would allow
104	isolation of the SQ-LNS effect (e.g., food rations alone).
105	
106	For comparisons of SQ-LNS with MMS, MMS was defined as including at least 3
107	micronutrients (19), and similar in form (e.g. tablet or capsule) to globally used MMS
108	formulations (20). We used the same exclusion criterion as Smith et al. (19), i.e., excluding
109	micronutrient powders because they provide additional nutrients compared to MMS tablets that
110	might have independent effects on the outcomes of interest.
111	
112	Search methods and identification of studies
113	We began the search by considering the studies identified by and included in the 2018 Cochrane
114	systematic review and meta-analysis of the provision of preventive LNS to pregnant women
115	(13). Then we repeated the database search methods employed in that review to capture any
116	studies published or registered as a randomized trial between January 2018 and September 2021.
117	There were no language restrictions. We searched the following international electronic
118	bibliographic databases: The Cochrane Library (Cochrane Central Register of Controlled Trials,
119	Cochrane Database of Systematic Reviews), MEDLINE (Ovid, In-Process and Other Non-
120	Indexed Citations Ovid, Epub ahead of print Ovid), EMBASE (Ovid), CINAHL Complete

121	(EBSCOhost), Web of Science (Social Sciences Citation Index, Science Citation Index,
122	Conference Proceedings Citation Index-Science, Conference Proceedings Citation Index-Social
123	Sciences), Epistemonikos (current issue), ClinicalTrials.gov, and WHO International Clinical
124	Trials Registry Platform. In addition, we searched nine regional databases: IBECS, SciELO
125	(Scientific Electronic Library Online), AIM (Africa Index Medicus), IMEMR (Index Medicus
126	for the Eastern Mediterranean Region), LILACS (Latin American and Caribbean Health
127	Sciences Literature), IRIS (PAHO/WHO Institutional Repository for Information Sharing)
128	WPRIM (Western Pacific Index Medicus), IMSEAR (Index Medicus for the South-East Asian
129	Region), and Native Health Research Database.
130	
131	After reviewing the titles and abstracts of all studies included in the previous review, as well as
132	the additional studies identified by the database searches, we selected all potentially relevant
133	studies for full text review and screened them based on the inclusion and exclusion criteria. After
134	completing the search, we communicated with investigators of all potentially eligible studies in
135	progress, regardless of whether the results had been published.
136	
137	Data collection and harmonization
138	We invited the principal investigators of eligible studies published or in progress to participate in
139	this IPD meta-analysis, and we provided a data dictionary listing definitions of variables
140	requested. Each contacted investigator provided de-identified individual participant datasets with
141	those variables to the IPD analyst (CDA), who communicated with investigators to request any
142	missing variables or other clarifications, as needed.

#### 144 *IPD integrity*

We conducted a complete-case intention-to-treat analysis (21). We evaluated whether the study sample sizes in our pooled data set were the same as in study protocols and publications. To address missing outcome data, we tabulated the percentage of participants lost to follow-up between enrollment and the assessment of the outcomes for each study. We also assessed whether missing data were differential with respect to intervention group by comparing rates of missingness across randomized arms.

151

152 We flagged biologically implausible values. For anthropometric outcomes, we calculated zscores using the 2006 WHO child growth standards (22, 23) and the INTERGROWTH standards 153 (24), checked the values for acceptable SDs, and flagged implausible values if they were outside 154 155 of published WHO acceptable ranges (22, 23). Implausible values were inspected for errors and either winsorized (25) if within 2 SD of the WHO acceptable ranges or removed from analysis if 156 clearly impossible on an outcome-by-outcome basis. Such cleaning was necessary for <0.2% of 157 participants. There was a consistently low rate of implausibility across outcomes and studies. We 158 also checked summary statistics from the harmonized data-set (e.g., means and SDs) against each 159 160 trial's published values.

161

162 Assessment of risk of bias in each study and quality of evidence across studies

163 Two independent reviewers (KRW and CDA) assessed risk of bias in each trial against the

164 following criteria: random sequence generation and allocation concealment (selection bias),

blinding of participants and personnel (performance bias), blinding of outcome assessment

166 (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and

167	other sources of bias (26). Any discrepancies were resolved by discussion or consultation with
168	the core working group, as needed. KRW, CDA and CPS assessed the quality of evidence for
169	anthropometric outcomes across all trials based on the 5 Grading of Recommendations
170	Assessment, Development and Evaluation (GRADE) criteria: risk of bias, inconsistency of
171	effect, imprecision, indirectness, and publication bias (27).
172	
173	Specification of outcomes and effect measures
174	We prespecified all outcomes in the SAP (17). As shown in <b>Box 1</b> , there were 3 categories of
175	outcomes: 1) birth size and duration of gestation, 2) anthropometric outcomes at 6 mo of age,
176	and 3) adverse outcomes (miscarriage, stillbirth, Cesarean-section, early neonatal mortality,
177	neonatal mortality, and 0-6 mo mortality). Continuous birth size outcomes included values in
178	units of measurement (e.g., birth weight in g; birth length, head circumference and mid-upper
179	arm circumference (MUAC) in cm), as z-scores (length-for-age z-score (LAZ), weight-for-age z-
180	score (WAZ), weight-for-length z-score (WLZ), BMI-for-age z-score (BMIZ), and head
181	circumference-for-age z-score (HCZ)) based on WHO Child Growth Standards at birth (22, 23)),
182	and as z-scores for gestational age (weight-for-gestational age z-score (WGAZ), length-for-
183	gestational age z-score (LGAZ) and head circumference-for-gestational age z-score (HCGAZ)
184	based on INTERGROWTH-21st standards (24)). At birth, BMIZ was used instead of WLZ
185	because the latter cannot be calculated for children with lengths <45 cm and exclusion of those
186	infants would create bias; when WLZ can be calculated these 2 variables are highly correlated
187	(r>0.90). For continuous outcomes based on INTERGROWTH-21st standards, we excluded
188	participants without ultrasound data for calculation of gestational age. Binary birth size outcomes
189	included low birth weight (LBW, < 2500 g), birth weight < 2000 g, small-for gestational age

190	(SGA, < 10th percentile based on INTERGROWTH-21st), large-for-gestational age (LGA,
191	>90th percentile based on INTERGROWTH-21st), newborn stunting (LAZ < -2 SD), low LGAZ
192	(< -2 SD), low BMIZ (< -2 SD), low HCZ (< -2 SD), and low HCGAZ (< -2 SD). Duration of
193	gestation was expressed in wk, and preterm birth was defined as delivery < 37 wk. For binary
194	outcomes based on gestational age, we retained participants without ultrasound dating but
195	conducted a sensitivity analysis in which they were excluded.

196

For continuous outcomes, the principal measure of effect was the mean difference (MD) between 197 198 intervention and comparison groups; for binary outcomes it was the relative risk (RR) for birth outcomes and adverse outcomes, and the prevalence ratio (PR; relative difference in proportions 199 200 between groups) for anthropometric outcomes at 6 mo of age. We also estimated the effect for 201 binary outcomes as the absolute differences between intervention groups in events per 1000 individuals. The absolute differences are useful for assessing public health impact, but we 202 considered them secondary outcomes because they can be less consistent than RRs or PRs across 203 204 studies (26).

205

The comparisons of interest were 1) SQ-LNS vs IFA/SOC and 2) SQ-LNS vs MMS. Study arms in which SQ-LNS began prior to conception were excluded from the main analyses because the objectives were to evaluate effects of SQ-LNS when given during pregnancy; however, the preconception study arms were included in sensitivity analyses.

210

211 Synthesis methods and exploration of variation in effects

212	We followed the same procedures for analysis as described previously (28), which included
213	evaluation of full sample main effects of the intervention as well as effect modification by
214	individual-level characteristics. We had also planned to evaluate effect modification by study
215	level characteristics (17) but only 4 eligible trials were identified, so there was inadequate
216	statistical power for study-level effect modification; thus those analyses are not described herein.
217	
218	Briefly, we followed a two-stage meta-analysis approach (29). In the first stage, intervention
219	effect estimates (or effect modification interaction term estimates) were generated within each
220	individual study according to its study design. In the second stage, the first-stage estimates were
221	pooled using both inverse-variance fixed effects and random effects.
222	
223	The individual-level characteristics considered as potential effect modifiers were similar to those
224	included in our previous IPD meta-analysis of trials using child SQ-LNS (28). The potential
225	effect modifiers for this analysis are shown in <b>Box 2</b> .
226	
227	We assessed heterogeneity of effect estimates using $I^2$ and $Tau^2$ statistics, within strata when
228	relevant (30). We used a P value <0.05 for main effects and a p-for-interaction < 0.10 for effect
229	modification by individual-level characteristics. Given that the birth outcomes are highly
230	correlated and the effect modification analyses are inherently exploratory, we did not adjust for
231	multiple hypothesis testing because doing so may be unnecessary and counterproductive (31).
232	
233	Additional sensitivity analyses
234	We pre-specified several sensitivity analyses:

235	• Exclusion of trials with a high level of missingness (>20%) of outcome data relative to
236	enrollment for pregnancy outcomes and relative to live births for later outcomes.
237	• For outcomes that rely on gestational age, exclusion of individuals for whom there is no
238	ultrasound dating of the gestational age of the fetus.
239	• For birth outcomes (e.g., infant anthropometry), exclusion of individuals for whom data
240	were collected >72 hours after birth.
241	• Exclusion of studies in which additional LNS was provided to certain mothers (e.g., those
242	with low BMI or gestational weight gain).
243	• Inclusion of trials/arms that provided SQ-LNS prior to conception (pooled main effects
244	only).
245	
246	Results
247	Literature search and study characteristics
248	We identified 4 trials that met our selection criteria and were completed in time to be included in
249	our analyses, all of which provided IPD (Figure 1, Table 1). The trials were conducted in

Bangladesh (32), Ghana (33), Malawi (34), and Guatemala (35) between 2009 and 2017. The

251 Guatemala study was one of 4 sites in the Women First trial (35). In that trial, an unfortified LNS

252 (in addition to SQ-LNS) supplying 300 kcal/d was provided to intervention group women who

253 were either underweight or who had inadequate gestational weight gain. In 3 of the 4 study sites

254 (Democratic Republic of the Congo, India, and Pakistan), >90% of enrolled women in the

- intervention groups received this supplement in addition to SQ-LNS, so the total amount of LNS
- provided to them was ~418 kcal/d, which would be categorized as MQ-LNS rather than SQ-

LNS. Therefore, only the Guatemala site is included in these analyses (where < 10% of enrolled</li>
women received the unfortified LNS in addition to SQ-LNS).

259

All 4 trials provided data for the comparison of SQ-LNS vs IFA/SOC; in 3 trials IFA was 260 provided to this comparison group (32-34), and in 1 trial (Guatemala) the comparison group 261 262 received SOC (biweekly visits to monitor pregnancy status) (35). Two of the 4 trials (Ghana and Malawi) also included an arm that received MMS and thus provided data for the comparison of 263 SQ-LNS vs MMS (33, 34). In Ghana and in the "complete follow-up" cohort in Malawi (who 264 265 received supplementation beyond pregnancy, see Table 1), SO-LNS and MMS were provided until 6 mo postpartum and IFA was provided until delivery followed by placebo (low dose 266 calcium) until 6 mo postpartum; in the "simplified follow-up" cohort in Malawi 267 268 (supplementation only during pregnancy), SQ-LNS, MMS or IFA were provided only until delivery (33, 34). In Bangladesh, SQ-LNS was provided until 6 mo postpartum and IFA until 3 269 mo postpartum (32), and in Guatemala, SQ-LNS was provided only until delivery (35). The 270 nutrient composition of SQ-LNS was nearly identical across trials (Supplemental Table 1), 271 except for more vitamin D and less zinc in the version used in Guatemala. The MMS used in 272 273 Ghana and Malawi was a formulation designed to match the micronutrient content of the SQ-LNS (11), which was based in part on results of a trial in Guinea-Bissau (36) that demonstrated a 274 275 greater impact on birth weight when the MMS contained 2X (vs 1X) the recommended dietary 276 allowance of most of the nutrients (except for iron, folic acid and vitamin A). Thus, the MMS used in Ghana and Malawi had higher levels of most of the micronutrients compared to the 277 278 United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) (37). 279

16

280	Mean gestational age when prenatal supplementation began was ~12 wk in Guatemala, ~13 wk
281	in Bangladesh, and 16-17 wk in Ghana and Malawi (Table 1). Mean maternal age was lowest in
282	Bangladesh (~22 y) and 24-27 y in the other sites. Mean maternal BMI was lowest in
283	Bangladesh (20.1 kg/m <sup>2</sup> ) and Malawi (20.5 kg/m <sup>2</sup> ), and was considerably higher in Ghana and
284	Guatemala (~24-25 kg/m <sup>2</sup> ). The proportion of women who were nulliparous at enrollment was
285	highest in Bangladesh and lowest in Guatemala. In the 3 sites in which household food insecurity
286	was assessed (Ghana, Malawi and Bangladesh), the percentage reporting moderate or severe
287	food insecurity ranged from 30% in Ghana to 66% in Malawi. Additional information on
288	maternal, child and household characteristics is available in Supplemental Table 2.
289	
290	The study populations differed with regard to risk of adverse birth outcomes, with Bangladesh
291	having the highest incidence (in the IFA/SOC group) of LBW (37%), SGA (59%), newborn
292	stunting (23%), low BMIZ (34%) and preterm birth (14%) (Supplemental Table 3). The
293	incidence of these outcomes in the IFA/SOC groups in the other 3 sites was 13-14% for LBW,
294	22-27% for SGA, 10-17% for newborn stunting, 6-11% for low BMIZ, and 8-12% for preterm
295	birth. Study-level data on anthropometric outcomes at 6 mo of age and adverse outcomes in the
296	IFA/SOC groups are available in Supplemental Tables 4-5.
297	
298	All trials were judged to have low risk of bias for 6 of the 7 categories: random sequence

300 incomplete outcome, selective reporting, and "other" (Supplemental Table 6 and Supplemental

**Figure 1).** All trials had a high risk of bias for blinding of participants, as blinding was not

302 possible given the physical difference in the supplements provided.

17

303

#### 304 SQ-LNS vs IFA/SOC

305 *Main effects* 

- For most birth outcomes, all 4 trials contributed to the pooled effect estimates and the total
- sample size was 4,922-5,348 (**Table 2**). For continuous birth outcomes based on
- 308 INTERGROWTH-21st standards, we excluded participants without ultrasound data, as
- mentioned above, and as a result only 3 trials contributed to the estimates for WGAZ, LGAZ and
- 310 HCGAZ (total n ~1,460-1,717).
- 311 Maternal SQ-LNS had a significant positive effect on all of the continuous birth outcomes, with
- a MD compared to IFA/SOC of +49 g for birth weight, +0.2 cm for birth length, +0.10-0.13 z-

scores for WAZ, WGAZ, LAZ, LGAZ, BMIZ, HCZ, and HCGAZ, +0.08 cm for MUAC, and

+0.12 wk for duration of gestation. Maternal SQ-LNS reduced the risk of LBW by 11%,

newborn stunting by 17%, low BMIZ by 11%, and low HCZ by 11%. Effect estimates for the

- other binary birth outcomes were not statistically significant but were in the same direction
- 317 (except for LGA, RR 1.00 (0.61, 1.65)).

We rated the quality of the evidence for all birth outcomes as moderate based on the GRADE criteria listed in the Methods: 3-4 RCTs were available for all outcomes, risk of bias was low except for blinding of participants, heterogeneity was low, precision was rated as high because all trials had sample sizes > 400, all trials were directly aimed at evaluating SQ-LNSs, and funnel plots revealed no indication of publication bias.

In general, there was consistency across studies in the direction of effects, with very low
 heterogeneity based on I<sup>2</sup> values (Figures 2A-F for birth weight, LBW, newborn LAZ, newborn

HCZ, newborn BMIZ and duration of gestation; Supplemental Figures 2A-BM for all 325 outcomes). Low I<sup>2</sup> values may be attributable to relatively wide CIs for some of the point 326 estimates rather than low variability in the RRs. For nearly all outcomes, fixed effects and 327 random-effects models generated identical estimates. 328 With regard to the sensitivity analyses, no trials had a high level of missingness of outcome data, 329 330 so no sensitivity analyses for that reason were needed. When including only ultrasound dating for outcomes dependent on gestational age (which excluded the Bangladesh trial), the magnitude 331 of the effect estimates increased but effects remained non-significant: RR=0.86 (0.73, 1.01) for 332 333 SGA (n=1,717), MD=0.15 (-0.03, 0.33) for duration of gestation (n=1,880) and RR=0.90 (0.68, 1.18) for preterm birth (n=1,880) (Supplemental Table 7A). For the other sensitivity analyses, 334 335 restricting birth size outcomes to data collected within 72 h of birth, or excluding the Guatemala trial (in which some women received additional LNS), or including the pre-conception arm of 336 the Guatemala trial, there was very little change in the findings. 337 338 For most of the effects of SQ-LNS vs IFA/SOC on anthropometric outcomes at 6 mo of age, all 339 4 trials contributed to the pooled estimates and the total sample size was  $\sim$ 5.030; outcomes based 340 341 on MUACZ were not available for Guatemala (Table 3). Maternal SQ-LNS reduced underweight at 6 mo (PR 0.85 (0.73, 0.99)), but effects on the other outcomes were not 342 statistically significant. In sensitivity analyses, the PR for underweight became non-significant 343

when Guatemala was excluded (0.96 (0.80, 1.16)) (with or without exclusion of the "simplified follow-up" cohort in Malawi; in this cohort and in Guatemala, maternal supplementation did not continue after delivery). The PR for underweight was not strengthened when the pre-conception

arm was included for Guatemala (0.90 (0.78, 1.13)). For other outcomes, these sensitivity
analyses did not substantively alter the findings (Supplemental Table 7B).

349

There were no significant differences in any of the adverse outcomes for the SO-LNS vs 350 IFA/SOC comparison, and the RR was generally < 1 except for incidence of stillbirths (Table 4). 351 352 Because of uncertainty in gestational age dating, it is sometimes difficult to distinguish between miscarriage and stillbirths (i.e., before vs. after 28 wk gestation), and in low resource settings it 353 can also be difficult to differentiate between stillbirth and early neonatal death (34). For these 354 355 reasons, Table 4 includes comparisons for 2 composite variables for these outcomes (miscarriage or stillbirth; miscarriage or stillbirth or early neonatal mortality). The RRs for those composite 356 adverse outcomes were both < 1.0. Adverse outcome findings were similar in the sensitivity 357 analyses (Supplemental Table 7C). 358

359

### 360 *Effect modification by individual-level characteristics*

For several characteristics, the p-for-interaction was > 0.10 for all or almost all infant birth 361 outcomes, i.e., effect modification was generally not evident for child birth order, maternal 362 363 height, education, or anemia at baseline, gestational age at start of supplementation, compliance with supplementation, household socio-economic status or sanitation (see Supplemental 364 Figures 3A-N for results stratified by all characteristics). For 5 characteristics, the p-for-365 366 interaction was < 0.10 for at least 2 birth outcomes, and data from at least 3 trials were available (Figures 3A-J show 12 selected birth outcomes for each of these characteristics, though the 367 number of outcomes for which p-for-interaction was < 0.10 varied). The estimated effects of 368 maternal SQ-LNS on birth outcomes were greater among a) female (vs. male) infants, for birth 369

370	weight, WAZ, LBW, birth weight < 2 kg, BMIZ, low BMIZ, HCZ, duration of gestation, and
371	preterm birth; b) women with lower BMI (< 20 vs. $\geq$ 20 kg/m <sup>2</sup> ), for MUAC and low infant HCZ;
372	c) younger women (< 25 vs. $\geq$ 25 y), for duration of gestation and birth weight <2 kg (although a
373	greater effect on SGA was seen among women $\geq$ 25 y); d) women with inflammation at baseline
374	(vs. without inflammation), for WAZ (Supplemental Figure 3H1), duration of gestation and low
375	infant HCZ; and e) women with greater household food insecurity (moderate to severe vs. mild
376	or secure), for birth length (Supplemental Figure 3M1), LAZ, head circumference (Supplemental
377	Figure 3M1) and newborn stunting. Only 2 trials had information on maternal malaria at
378	baseline, but in those trials the effect estimates for maternal SQ-LNS were greater among women
379	with a positive rapid test for malaria at baseline (vs. those with a negative test) for birth weight,
380	WAZ, LBW and SGA (Supplemental Figures 311-2). In sensitivity analyses including only
381	ultrasound dating for outcomes dependent on gestational age (Supplemental Table 8), the
381 382	ultrasound dating for outcomes dependent on gestational age ( <b>Supplemental Table 8</b> ), the interaction with child sex was still evident for duration of gestation but not preterm birth; the
382	interaction with child sex was still evident for duration of gestation but not preterm birth; the
382 383	interaction with child sex was still evident for duration of gestation but not preterm birth; the interaction with maternal age was still significant (and stronger) for duration of gestation but not
382 383 384	interaction with child sex was still evident for duration of gestation but not preterm birth; the interaction with maternal age was still significant (and stronger) for duration of gestation but not for SGA; the interaction with maternal inflammation became weaker for duration of gestation;
382 383 384 385	interaction with child sex was still evident for duration of gestation but not preterm birth; the interaction with maternal age was still significant (and stronger) for duration of gestation but not for SGA; the interaction with maternal inflammation became weaker for duration of gestation; and there was no change in the interaction with maternal malaria for SGA. In sensitivity analyses
382 383 384 385 386	interaction with child sex was still evident for duration of gestation but not preterm birth; the interaction with maternal age was still significant (and stronger) for duration of gestation but not for SGA; the interaction with maternal inflammation became weaker for duration of gestation; and there was no change in the interaction with maternal malaria for SGA. In sensitivity analyses restricted to anthropometric outcomes assessed within 72 h of birth, results were generally
382 383 384 385 386 387	interaction with child sex was still evident for duration of gestation but not preterm birth; the interaction with maternal age was still significant (and stronger) for duration of gestation but not for SGA; the interaction with maternal inflammation became weaker for duration of gestation; and there was no change in the interaction with maternal malaria for SGA. In sensitivity analyses restricted to anthropometric outcomes assessed within 72 h of birth, results were generally stronger for the interactions with child sex and maternal inflammation, similar for maternal BMI,
382 383 384 385 386 387 388	interaction with child sex was still evident for duration of gestation but not preterm birth; the interaction with maternal age was still significant (and stronger) for duration of gestation but not for SGA; the interaction with maternal inflammation became weaker for duration of gestation; and there was no change in the interaction with maternal malaria for SGA. In sensitivity analyses restricted to anthropometric outcomes assessed within 72 h of birth, results were generally stronger for the interactions with child sex and maternal inflammation, similar for maternal BMI, age, and household food insecurity, and weaker for maternal malaria (for birth weight and LBW,

We explored whether the greater effect of SQ-LNS on birth size outcomes among females (vs.
males) could be attributed mainly to the mediating effects on duration of gestation: when
including duration of gestation in the models, the p-for-interaction was > 0.10 for birth weight,
WAZ, BMIZ and HCZ but remained < 0.10 for LBW, birth weight < 2 kg, and low BMIZ</li>
(available at https://osf.io/nj5f9/(17)).

397 Some of the above characteristics also modified the effect estimates for maternal SQ-LNS vs. IFA/SOC with respect to infant anthropometric outcomes at 6 mo, particularly infant sex. Effect 398 399 estimates were larger for females than for males, as was the case for the birth outcomes (Figure 400 4). Among females, maternal SQ-LNS was associated with a 26% reduction in underweight and a 30% reduction in low HCZ, whereas there was no reduction among males. These findings were 401 402 very similar in the sensitivity analyses excluding Guatemala (with or without exclusion of the "simplified follow-up" cohort in Malawi) (available at https://osf.io/nj5f9/ (17)). For 3 other 403 characteristics, the p-for-interaction was < 0.10 for at least 2 distinct infant outcomes at 6 mo. 404 Effect estimates for maternal SQ-LNS were greater among a) women with greater food 405 insecurity, for LAZ and underweight at 6 mo (Supplemental Figures 3M3-4); b) women with 406 improved sanitation, for WAZ and WLZ at 6 mo (Supplemental Figure 3N3); and c) later-born 407 children, for underweight and stunting at 6 mo (Supplemental Figure 3B4). 408

Supplemental Figures 4A-N present pooled estimates for adverse outcomes, stratified by
potential individual-level effect modifiers. For many of the potential effect modifiers, the p-forinteraction was > 0.10 for all of the adverse outcomes; for several other potential effect
modifiers, the p-for-interaction was < 0.10 for only one adverse outcome, and for that outcome</li>
the difference between SQ-LNS and IFA/SOC groups was not significant in either subgroup. For
birth order, the p-for-interaction was < 0.10 for 2 outcomes: neonatal mortality and mortality 0-6</li>

- 415 mo. In both cases, the stratum-specific estimates were not significant: neonatal and 0-6 mo
- 416 mortality RRs were respectively 0.54 (0.27, 1.06) and 0.60 (0.32, 1.15) among first-born infants,
- and 1.08 (0.69, 1.70) and 1.22 (0.86, 1.73) among later-born infants. These results were similar
- 418 in the sensitivity analyses (available at https://osf.io/nj5f9/ (17)).

#### 419 SQ-LNS vs MMS

- 420 *Main effects*
- 421 Effects of SQ-LNS vs MMS on birth outcomes are based on 2 trials and a total sample size of
- 422 1,121-1,539 (Table 5). There were marginally significant differences in head circumference
- 423 (+0.14 (-0.02, 0.31) cm) and HCGAZ (+0.11 (-0.01, 0.23)) favoring the SQ-LNS group, but p-
- 424 values for all other outcomes were > 0.10. There was low heterogeneity, and fixed effects and
- random-effects models generated nearly identical estimates (Figures 5A-C and Supplemental
- 426 Figures 5A-AF). We rated the quality of the evidence for all outcomes as low because data were
- 427 available for only 2 trials, both conducted in Africa.
- 428 Most of the pre-planned sensitivity analyses were not applicable to these 2 trials, except for the
- 429 one restricting birth size outcomes to data collected within 72 h of birth. In that sensitivity
- 430 analysis, there was little change in the results except that the MDs for head circumference (+0.21
- 431 (-0.03, 0.45)) and HCGAZ (+0.16 (-0.01, 0.34)) became larger (though still marginally
- 432 significant).
- **Table 6** shows that there were no significant effects of SQ-LNS vs MMS on anthropometric
- 434 outcomes at 6 mo of age. Findings were not altered when excluding the "simplified cohort
- 435 follow-up" in Malawi. Table 7 shows no significant differences in adverse outcomes for the SQ-
- 436 LNS vs MMS comparison.

#### 437 *Effect modification by individual-level characteristics*

For most characteristics, the p-for-interaction was > 0.10 for all infant birth outcomes, i.e., effect 438 439 modification was not evident for maternal height, BMI, education, or anemia at baseline, 440 gestational age at start of supplementation, compliance with supplementation, household socioeconomic status, food insecurity, or sanitation (Supplemental Figures 6A-M). The p-for-441 442 interaction was < 0.10 for at least 1 birth size outcome for 5 characteristics: child sex, birth order, maternal age, inflammation at baseline, and malaria at baseline. Effect modification estimates for 443 maternal SQ-LNS vs MMS were greater (p-for-interaction < 0.10) among a) female (vs. male) 444 infants for head circumference, HCZ, birth weight < 2 kg, SGA, low BMIZ and low HCZ 445 (Supplemental Figures 6A1-2), b) first-born (vs. later-born) infants for birth weight and WAZ 446 (Supplemental Figure 6B1), and c) younger women (< 25 vs. > 25 y) for SGA (Supplemental 447 Figure 6E). Effect modification by maternal inflammation was difficult to interpret: effect 448 estimates for maternal SQ-LNS vs. MMS were greater among women with inflammation for 449 birth weight, but greater among those without inflammation for HCZ and HCGAZ 450 (Supplemental Figure 6H1). Results for effect modification by maternal malaria were not 451 452 interpretable because they could not be confirmed in the sensitivity analysis restricted to anthropometric outcomes measured within 72 h of birth, due to insufficient sample sizes in the 453 subgroup with malaria at enrollment. Results of the sensitivity analysis restricted to birth size 454 measured within 72 h for effect modification by child sex, birth order and maternal age are 455 456 available at https://osf.io/nj5f9/ (17); the findings were similar but for some outcomes the sample sizes in certain subgroups were insufficient to generate effect estimates. 457

1.0. 1.1

00

1 0 0 1 1 0

458	Some of the above characteristics also modified the effect estimates for maternal SQ-LNS vs.
459	MMS with regard to a few of the anthropometric outcomes at 6 mo, but the results were not
460	always consistent across outcomes (Supplemental Figures 6A3&4-6M3&4).
461	For most of the adverse outcomes, statistical power to examine effect modification was low
462	because they are rare events and the total sample size for this comparison, with both trials
463	combined, was $\leq$ 1,566.

464

465

#### 466 **Discussion**

467 In this IPD meta-analysis, data from 4 trials showed that maternal SQ-LNS, compared to IFA or 468 SOC, increased mean birth weight, length, head circumference, BMIZ, MUAC and duration of 469 gestation, and on average reduced the incidence of LBW by 11%, newborn stunting by 17%, 470 newborn wasting (low BMIZ) by 11%, and small head size (low HCZ) by 15%. Only 2 trials directly compared maternal SQ-LNS and MMS; birth outcomes did not differ significantly 471 472 between these groups, although there was a marginally significant difference in newborn head 473 circumference. Several individual-level characteristics appeared to modify the impact of maternal SQ-LNS. For the comparison with IFA or SOC, effect estimates for SQ-LNS were 474 greater among female infants and among women with  $BMI < 20 \text{ kg/m}^2$ , inflammation or malaria 475 476 at enrollment, or greater household food insecurity. For the comparison with MMS, effect estimates for SQ-LNS were greater among female infants, first-born infants, and women < 25 y 477 of age. Some of these findings may have implications with regard to potential targeting of SQ-478 LNS to vulnerable women, as discussed below. 479

#### 480 Main effects on birth outcomes and adverse outcomes

481	For SQ-LNS vs IFA/SOC, our estimated main effects for birth outcomes are similar to those of
482	Das et al. (13), which is expected because their analysis included 3 of the 4 trials in our IPD
483	analysis. We report on several birth outcomes not included in the Das et al. meta-analysis:
484	newborn BMIZ and low BMIZ, and birth size for gestational age outcomes using the
485	INTERGROWTH-21st standard. The MD in birth weight was 49 g, which is similar to the
486	estimated impact of other types of BEP (10). The RR of 0.89 for LBW translates into an
487	estimated absolute difference of ~29 events per 1000 births. For newborn stunting, wasting, and
488	small head size, the estimated absolute differences are 32, 24 and 22 events per 1000 births,
489	respectively. For SGA (RR 0.96 (0.92, 1.01)), the upper bound of the 95% CI slightly exceeded
490	1.0; in a sensitivity analysis restricted to results based on ultrasound dating of gestational age
491	(which required exclusion of the largest trial, in Bangladesh), the RR was more substantial but
492	the upper bound of the 95% CI did not change (0.86 (0.73, 1.01)). The RR for preterm birth was
493	not significant in the main analysis (0.94 (0.80, 1.10)) or in the sensitivity analysis restricted to
494	ultrasound dating (0.90 (0.68, 1.18)). The effect estimates for birth size z-scores for gestational
495	age (+0.13 in WGAZ, +0.13 in LGAZ, and +0.11 in HCGAZ) were similar to those for WAZ
496	(+0.12), LAZ (+0.11) and HCZ (+0.10), suggesting that the impact of SQ-LNS on birth size was
497	mainly attributable to improvements in fetal growth.

498 For SQ-LNS vs MMS, we cannot directly compare our estimated main effects to those of Das et

al. (13) because their analysis included 1 MQ-LNS trial in addition to the 2 SQ-LNS trials that

- are in our IPD meta-analysis. Although neither meta-analysis showed significant differences in
- 501 birth outcomes between (SQ-)LNS and MMS groups, the MDs for all of the birth size outcomes
- in our IPD analysis were in the same direction as those for the SQ-LNS vs IFA/SOC analysis,

503	though generally of lower magnitude except for the MD in head circumference (which was
504	almost identical between the SQ-LNS vs MMS and SQ-LNS vs IFA/SOC comparisons, e.g.,
505	HCGAZ +0.11 (-0.01, 0.23) and +0.11 (0.02, 0.20), respectively).
506	Because only 2 trials have directly compared SQ-LNS with MMS, it is useful to examine how
507	the estimated effects of SQ-LNS vs IFA/SOC compare with those of MMS vs IFA in previous
508	meta-analyses, which included a large number of trials (19, 38). Effects of MMS vs IFA on mean
509	birth weight (+48 (40, 57) g in Smith et al. (19)) and RR for LBW (0.86-0.88) (19, 38) are quite
510	similar to those shown for SQ-LNS vs IFA/SOC herein, and the results for SGA and preterm
511	birth are also similar. However, we have demonstrated positive effects of SQ-LNS on newborn
512	LAZ, stunting, HCZ, and small HCZ, whereas these outcomes have not been reported in the
513	MMS vs IFA meta-analyses. The MD for head circumference in the SQ-LNS vs MMS
514	comparison suggests that the differences in nutrient composition between these two supplements
515	(e.g., inclusion of EFAs, calcium in SQ-LNS) may influence certain parameters of fetal growth,
516	even if effects on birth weight are similar.
517	In both the SQ-LNS vs IFA/SOC and SQ-LNS vs MMS comparisons, we did not find significant
518	differences in incidence of Cesarian-section, miscarriage, stillbirths, early neonatal mortality,
519	neonatal mortality or mortality from birth to 6 mo of age, although it should be noted that the
520	statistical power to detect differences in some of these rare outcomes was particularly limited.
521	Effect modification for birth outcomes

522 SQ-LNS vs IFA/SOC

523 The impact of SQ-LNS was greater among female than among male infants for many of the birth

524 outcomes. Among females, effect estimates for SQ-LNS suggested reductions of 20% for LBW,

525	24%, for newborn stunting, 22% for newborn wasting and 17% for small head size, and an
526	increase in duration of gestation of $+0.3$ (0.15, 0.45) wk. In exploratory analyses, we found that
527	the effects on birth size were only partially explained by the increased duration of gestation,
528	suggesting that among female fetuses, SQ-LNS influenced both of the pathways leading to
529	SVNs, i.e., "born too soon" and "born too small" (6). It is noteworthy that child sex did not
530	modify the effects of MMS (vs IFA) on LBW or SGA (19). It is unclear why the effects of SQ-
531	LNS were stronger among female fetuses. In our previous IPD meta-analysis of SQ-LNS
532	provided directly to infants and young children 6-23 mo of age, we also found a greater impact
533	among females than among males for child stunting, wasting and small head size (15), as well as
534	anemia (39). We interpreted this as a greater potential to respond to nutritional interventions
535	among females than among males (15). Males are more vulnerable to environmental stressors
536	(40, 41), and are at higher risk of morbidity and mortality in early life, which could constrain
537	their response to nutrition interventions. Our results suggest that this vulnerability begins prior to
538	birth and is thus likely to be biologically rather than socially driven.
539	For some outcomes, effects of SQ-LNS were greater among mothers with a low BMI at
540	enrollment than among those with BMI $\geq$ 20 kg/m <sup>2</sup> . The p-for-interaction was significant only
541	for low HCZ and mean MUAC but effect estimates were also somewhat larger among low BMI
542	mothers for most of the other birth size outcomes (though not for duration of gestation or preterm
543	birth). Among mothers with low BMI, effect estimates for SQ-LNS suggested reductions of 23%
544	for newborn small head size and 20% for newborn stunting. This could be interpreted as a
545	greater potential to benefit among infants of low BMI mothers.
546	Similarly, effects of SQ-LNS were greater among infants of women with inflammation or

547 malaria at enrolment. For inflammation, the p-for-interaction was significant for WAZ, duration

548	of gestation and small head size and there was a similar pattern for several other birth outcomes.
549	Among women with inflammation, effect estimates for SQ-LNS suggested reductions of 33% for
550	LBW, 31% for newborn stunting, 33% for newborn wasting and 40% for small head size. For
551	malaria, the p-for-interaction was significant for birth weight, WAZ, LBW, and SGA. Among
552	women with malaria, effect estimates for SQ-LNS suggested reductions of 47% for LBW and
553	40% for SGA. These are large relative reductions in the risk of being "born too small", and
554	suggest that SQ-LNS may be mitigating the adverse effects of maternal inflammation and
555	possibly malaria on fetal growth (42, 43).
556	Effects of SQ-LNS were also greater among women in households with moderate-to-severe food
557	insecurity than in those with less food insecurity. The p-for-interaction was significant for birth
558	length, LAZ, newborn stunting, and head circumference (in cm) and there was a similar pattern
559	for several other birth outcomes. Among women with greater food insecurity, effect estimates for
560	SQ-LNS suggested reductions of 16% for LBW and 25% for newborn stunting. These findings
561	suggest a greater potential to benefit among women with food insecurity, perhaps because they

are at greater risk of nutrient inadequacy.

Effects of SQ-LNS on birth size outcomes tended to be greater among infants of mothers who

consumed supplements  $\geq$  4 days/wk than in those with lower compliance, although the p-for-

565 interaction was significant only for stunting. Among women with higher compliance, effect

estimates for SQ-LNS suggested reductions of 16% for LBW, 22% for newborn stunting, 14%

for newborn wasting, and 18% for small head size.

568 Effect modification was generally not evident for other maternal characteristics. This could be

important, as it suggests that a response to maternal SQ-LNS is not constrained by short maternal

570 stature, low education, anemia at baseline, later gestational age at start of supplementation, or

571	low household socio-economic status. In the IPD meta-analysis of MMS vs IFA (19), there was a
572	greater impact of MMS on SGA among women with more education, compared to those with
573	less education. This type of interaction was not observed for SQ-LNS. The lack of interaction of
574	SQ-LNS with maternal anemia is also noteworthy because the iron content of SQ-LNS (20 mg)
575	was much lower than that of IFA (60 mg) in these trials. Although this difference in iron content
576	may influence the risk of maternal iron-deficiency anemia (44-46), it does not appear to
577	compromise the impact of maternal SQ-LNS on infant outcomes (47).

578

588

#### SQ-LNS vs MMS 579

As was found for the comparison of SQ-LNS vs IFA/SOC, effect estimates for SQ-LNS vs MMS 580

581 were greater among female than among male infants. The p-for-interaction with infant sex was

significant for several outcomes (HCZ, SGA, birth weight < 2 kg, low BMIZ, and small head 582

size), and the effect estimates for SQ-LNS were significant among females for LGAZ (+0.17 583

(0.00, 0.33)), HCZ (+0.21 (0.01, 0.40)) and HCGAZ (+0.19 (0.02, 0.37)). It is noteworthy that 584

these differences between intervention groups among females are for outcomes that reflect linear 585

growth and head size, and may be attributable to the differences in nutrient content between SQ-586

LNS and MMS, particularly EFAs (important for brain development) (48) and minerals such as 587

calcium, potassium and magnesium (important for linear growth).

589 Effects of SQ-LNS vs MMS appeared to be greater among first-born than among later-born

infants. The p-for-interaction was significant for birth weight and WAZ, and among first-born 590

infants the effect estimates for SQ-LNS were substantial for birth weight (+120 (35, 205) g) and 591

HCZ (+0.31 (0.05, 0.58)). However, there was heterogeneity between the 2 sites for this 592

interaction, with results being driven by greater effects of SQ-LNS among first-born infants inGhana but not in Malawi.

Effects of SQ-LNS on SGA were more beneficial among younger women than among those  $\geq 25$ 

596 y, and there was a similar pattern for other birth outcomes. Among infants of younger mothers,

effect estimates for SQ-LNS vs MMS were significant for birth weight (+69 (4, 135)), WAZ

598 (+0.16 (0.01, 0.31)), and HCZ (+0.20 (0.00, 0.40)). This could reflect a greater potential to

599 benefit among infants of younger mothers (who are also more likely to be first-born), among

600 whom improved intake of EFAs and certain minerals could be more critical.

#### 601 Effects on anthropometric status at 6 mo

An important biological and programmatic question is whether prenatal supplementation has a 602 603 sustained impact on infant growth status after birth. Previous evidence on this question has been mixed (49). In this meta-analysis, maternal SQ-LNS (compared to IFA or SOC) reduced the 604 prevalence of underweight at 6 mo of age by 15%, but effects on the other anthropometric 605 outcomes were not statistically significant. Among female infants, underweight at 6 mo was 606 reduced by 26%, whereas no effect was observed among male infants. In 3 cohorts (Bangladesh, 607 Ghana and half of the Malawi cohort), mothers continued to receive supplements after delivery 608 for up to 6 mo, so it is possible that some of the impact on infant underweight at 6 mo is 609 attributable to postpartum effects, e.g., through breast milk composition or maternal caregiving 610 611 capacity. However, when we excluded the two cohorts in which mothers did not continue to receive supplements postpartum (Guatemala and half of the Malawi cohort), the effect estimate 612 613 for underweight was weaker rather than stronger, suggesting that the reduction in underweight is 614 likely related to SQ-LNS received prenatally. This is an important finding because underweight among infants is a key risk factor for mortality (50-52). 615

616 There were no significant differences in infant anthropometric status at 6 mo in the comparison617 of SQ-LNS vs MMS.

#### 618 <u>Strengths and limitations</u>

Strengths of this IPD meta-analysis include the high quality of the randomized controlled trials 619 contributing to the estimates, data from diverse settings on 3 different continents, and the 620 consistency in findings between fixed-effects and random-effects models as well as in most of 621 the sensitivity analyses. Limitations include the relatively small number of trials (especially for 622 623 the SQ-LNS vs MMS comparison), and limited statistical power to detect differences in rare outcomes. Results of the effect modification analyses should be interpreted with caution because 624 many of the potential effect modifiers are interrelated and also may be confounded by other 625 626 unmeasured factors. In addition, there was variation in the methods used in each study to assess certain potential effect modifiers such as household food insecurity and socio-economic status. 627

628

#### 629 <u>Conclusions and implications</u>

Maternal SQ-LNS has substantial positive effects on birth outcomes when compared with IFA or 630 631 SOC, especially among female infants and among vulnerable women such as those with low BMI, inflammation or malaria at enrollment, or greater household food insecurity. Provision of 632 SQ-LNS to pregnant women may also reduce the prevalence of underweight among infants at 6 633 mo of age. An important programmatic question is whether maternal SQ-LNS is superior to 634 MMS, which is lower in cost and is currently being scaled-up (53, 54). Based on this meta-635 636 analysis as well as the meta-analyses of MMS (19, 38), we conclude that SQ-LNS and MMS have similar positive effects on birth weight outcomes when comparing each with IFA. 637

638	However, it is not known whether MMS has an impact on newborn LAZ, stunting, BMIZ,
639	wasting, HCZ, or small HCZ, all of which were improved in the SQ-LNS vs IFA/SOC
640	comparisons herein. With only 2 trials directly comparing SQ-LNS and MMS, the statistical
641	power to detect differences between intervention groups was considerably lower than was the
642	case for the SQ-LNS vs IFA/SOC comparison. Moreover, the MMS used in those 2 trials had
643	1.5-2 times the amounts of most micronutrients compared to the MMS formulation currently
644	being scaled up (UNIMMAP), which may have reduced the likelihood of detecting differences in
645	birth outcomes between the SQ-LNS and MMS groups. Further trials that include this
646	comparison are needed.
647	It is possible that the impact of SQ-LNS on certain birth outcomes is superior to that of MMS
648	within vulnerable populations, even if the main effects on those outcomes do not differ
649	significantly in the general population. For example, among infants of women < 25 y of age,
650	birth weight and head circumference were greater in the SQ-LNS group, compared to MMS. As
651	mentioned above, effects of SQ-LNS vs IFA/SOC were largest in more vulnerable women,
652	whereas effects of MMS (vs IFA) on birth size (LBW or SGA) have not been shown to differ in
653	such subgroups (i.e., younger women, those with low BMI) (19). The MMS vs IFA IPD meta-
654	analysis did not include household food insecurity or maternal inflammation as potential effect
655	modifiers.
656	The large and consistent impact of SQ-LNS (vs IFA/SOC) among women with one or more

biomarkers of inflammation at enrollment on several different metrics of fetal growth (ponderal,

- 658 linear and head size) is noteworthy, given that the percentage of women in this subgroup was
- 40.8% in Ghana, 45.9% in Malawi and 16.6% in Bangladesh (this information was not available

660 for Guatemala). These findings suggest a greater potential to benefit from maternal SQ-LNS among such women. The mechanisms underlying these findings require further investigation. 661 662 Further research is also needed to elucidate potential biological explanations for the stronger 663 effects of maternal SQ-LNS observed among female infants, compared to males, and how to overcome the constraints on response among males. Regardless of the mechanism, the 664 665 substantial reduction in risk of newborn stunting among females may have implications with regard to subsequent height during childhood, adolescence and adulthood (55, 56). Greater 666 667 maternal stature in females at the time of childbearing may reduce the risk of SGA and thereby help prevent the intergenerational transmission of impaired growth. 668 From a programmatic perspective, the effects among vulnerable subgroups demonstrated herein 669 670 suggest that targeting provision of SQ-LNS to younger women, those with low BMI, or those in households with food insecurity may be worth considering. This type of targeting is envisioned 671 for BEP interventions in general (9), and the 2016 WHO guideline on antenatal care (57) already 672 recommends prenatal BEP in populations with a high prevalence of undernutrition among 673 pregnant women. Given that SQ-LNS meets the definition of BEP, our results support the 674 strategy of targeting food-based supplements to pregnant women who have the greatest potential 675 to benefit. SQ-LNS provides less energy than most BEP supplements that have been evaluated, 676 but at present there is no clear dose-response relationship between the quantity of LNS (or BEP 677 678 of other types) and birth outcomes (58). Further research is needed to identify the optimal energy content of LNS for pregnant women. However, it is noteworthy that the effects of SQ-LNS (vs 679 IFA/SOC) on birth outcomes in this IPD analysis were larger among women with greater food 680 681 insecurity, despite the small amount of energy provided. This implies that improving intake of essential nutrients during pregnancy in high-risk populations is of paramount importance. 682

34

683

#### 684 Acknowledgments

- 685 We thank all of the co-investigators, collaborators, study teams, participants and local
- 686 communities involved in the trials included in these analyses. These trials benefitted from the
- 687 contributions of many partner organizations, including: icddr,b (Rang-Din Nutrition Study); the
- 688 International Lipid-based Nutrient Supplements Project Steering Committee (iLiNS Project
- trials); NICHD-Global Network for Women's and Children's Health Research and Institute of
- 690 Nutrition in Central America and Panama (INCAP) (Women First trial); and Nutriset (for
- 691 development of SQ-LNS).

692

- 693 The authors' responsibilities were as follows—KGD: drafted the manuscript with input from
- 694 KRW, CDA, CPS and other coauthors; KRW, CDA, KGD, and CPS: wrote the statistical
- analysis plan; BFA, PA, LH, NFK, JL, SM: reviewed, contributed to, and approved the statistical
- analysis plan; KRW and CDA: compiled the data; CDA: conducted the data analysis; and all
- authors: read, contributed to, and approved the final manuscript; KGD is responsible for final

698 content.

699

- 700Supported by Bill & Melinda Gates Foundation grant OPP49817 (to KGD). All authors report no
- 701 conflicts of interest.

## REFERENCES

- 1. Stevens G.A., Beal T., Mbuya M.N.N., Luo H., Neufeld L.M., Global Micronutrient Deficiencies Research G. Micronutrient deficiencies among preschool-aged children and women of reproductive age worldwide: a pooled analysis of individual-level data from population-representative surveys. Lancet Glob Health 2022;10:e1590-e9.
- 2. World Health Organization. Global Anaemia Estimates. 2021. Available at: https://www.who.int/data/gho/data/themes/topics/anaemia\_in\_women\_and\_children. Accessed on: 4 April 2022.
- 3. United Nations Children's Fund. UNICEF Programming Guidance. Prevention of malnutrition in women before and during pregnancy and while breastfeeding. New York: UNICEF, 2021. Available at:

https://www.unicef.org/media/114561/file/Maternal%20Nutrition%20Programming%20 Guidance.pdf. Accessed on: 18 March 2024.

- United Nations Children's Fund. UNICEF Data: Monitoring the situation of children and women. Women's Nutrition. 2021. Available at: https://data.unicef.org/topic/nutrition/womens-nutrition/#resources. Accessed on: 18 March 2024.
- 5. Torheim L.E., Ferguson E.L., Penrose K., Arimond M. Women in resource-poor settings are at risk of inadequate intakes of multiple micronutrients. J Nutr 2010;140:2051S-8S.
- 6. Ashorn P., Ashorn U., Muthiani Y., Aboubaker S., Askari S., Bahl R., et al. Small vulnerable newborns-big potential for impact. Lancet 2023;401:1692-706.
- 7. Lawn J.E., Ohuma E.O., Bradley E., Idueta L.S., Hazel E., Okwaraji Y.B., et al. Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting. Lancet 2023;401:1707-19.
- 8. Hunter P.J., Awoyemi T., Ayede A.I., Chico R.M., David A.L., Dewey K.G., et al. Biological and pathological mechanisms leading to the birth of a small vulnerable newborn. Lancet 2023;401:1720-32.
- 9. Hofmeyr G.J., Black R.E., Rogozinska E., Heuer A., Walker N., Ashorn P., et al. Evidencebased antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes. Lancet 2023;401:1733-44.
- Ota E., Hori H., Mori R., Tobe-Gai R., Farrar D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database of Systematic Reviews 2015:CD000032.
- 11. Arimond M., Zeilani M., Jungjohann S., Brown K.H., Ashorn P., Allen L.H., Dewey K.G. Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: Experience from the International Lipid-Based Nutrient Supplements (iLiNS) Project. Matern Child Nutr 2015;11 31-61.
- 12. USAID Advancing Nutrition. Small-Quantity Lipid-Based Nutrient Supplement Program implementation learnings and considerations for scale-up from International Food Relief Partnership partners in Honduras, Niger, and Somalia. Arlington, VA: USAID Advancing Nutrition. 2022. Available at: https://www.advancingnutrition.org/resources/smallquantity-lipid-based-nutrient-supplement-program-implementation. Accessed on: 12 April 2023.
- Das J.K., Hoodbhoy Z., Salam R.A., Bhutta A.Z., Valenzuela-Rubio N.G., Weise Prinzo Z., Bhutta Z.A. Lipid-based nutrient supplements for maternal, birth, and infant developmental outcomes. Cochrane Database of Systematic Reviews 2018;8:CD012610.

- 14. Hunter P.J., Muthiani Y., Nasanen-Gilmore P.K., Koivu A.M., Portfors P., Bastola K., et al. A modular systematic review of antenatal interventions to address undernutrition during pregnancy in the prevention of low birth weight. Amer J Clin Nutr 2023;117 Suppl 2:S134-S47.
- 15. Dewey K.G., Stewart C.P., Wessells K.R., Prado E.L., Arnold C.D. Small-quantity lipidbased nutrient supplements for the prevention of child malnutrition and promotion of healthy development: Overview of individual participant data meta-analysis and programmatic implications. Amer J Clin Nutr 2021;114:3S-14S.
- 16. Wessells R., Dewey K., Stewart C., Arnold C., Prado E. Modifiers of the effect of LNS provided to pregnant women on maternal, birth and infant outcomes: A systematic review and meta-analysis of individual participant data from randomized controlled trials in low-and middle-income countries. PROSPERO CRD42021283391. 2021. Available from: https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42021283391 Accessed on: 18 March 2024..
- 17. Wessells K.R., Dewey K., Arnold C.D., Stewart C., Prado E. Modifiers of the effect of LNS provided to pregnant women on maternal, birth and infant outcomes. Open Science Framework. 2021. Available at: https://osf.io/nj5f9/. Accessed on: 18 March 2024.
- World Bank Historical Classification by Income Group. Available at: http://databank.worldbank.org/data/download/site-content/OGHIST.xls Accessed on: 22 August 2019.
- 19. Smith E.R., Shankar A.H., Wu L.S., Aboud S., Adu-Afarwuah S., Ali H., et al. Modifiers of the effect of maternal multiple micronutrient supplementation on stillbirth, birth outcomes, and infant mortality: a meta-analysis of individual patient data from 17 randomised trials in low-income and middle-income countries. Lancet Glob Health 2017;5:e1090-e100.
- 20. WHO. WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update: Multiple micronutrient supplements during pregnancy. Geneva: World Health Organization, 2020.
- 21. Johnston B.C., Guyatt G.H. Best (but oft-forgotten) practices: intention-to-treat, treatment adherence, and missing participant outcome data in the nutrition literature. Am J Clin Nutr 2016;104:1197-201.
- 22. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization, 2006.
- 23. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Head circumference-for-age, arm circumference-for-age, triceps skinfold-for-age and subscapular skinfold-for-age: Methods and development. Geneva: World Health Organization, 2007.
- 24. Villar J., Cheikh Ismail L., Victora C.G., Ohuma E.O., Bertino E., Altman D.G., et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 2014;384:857-68.
- 25. Tukey J. The future of data analysis. The Annals of Mathematical Statistics 1962;33:1-67.
- Higgins J., Green S. Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0. The Cochrane Collaboration 2011. Available from www.handbook.cochrane.org.

- 27. Balshem H., Helfand M., Schunemann H.J., Oxman A.D., Kunz R., Brozek J., et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
- 28. Dewey K.G., Wessells K.R., Arnold C.D., Prado E.L., Abbeddou S., Adu-Afarwuah S., et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child growth: An individual participant data meta-analysis of randomized controlled trials. Amer J Clin Nutr 2021;114 (Suppl 1):15S-42S.
- 29. Burke D.L., Ensor J., Riley R.D. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med 2017;36:855-75.
- 30. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in metaanalyses. BMJ 2003;327:557-60.
- 31. Streiner D.L. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. Am J Clin Nutr 2015;102:721-8.
- 32. Mridha M.K., Matias S.L., Chaparro C.M., Paul R.R., Hussain S., Vosti S.A., et al. Lipidbased nutrient supplements for pregnant women reduce newborn stunting in a clusterrandomized controlled effectiveness trial in Bangladesh. Amer J Clin Nutr 2016;103:236-49.
- 33. Adu-Afarwuah S., Lartey A., Okronipa H., Ashorn P., Zeilani M., Peerson J.M., et al. Lipidbased nutrient supplement increases the birth size of infants of primiparous women in Ghana. Amer J Clin Nutr 2015;101:835-46.
- 34. Ashorn P., Alho L., Ashorn U., Cheung Y.B., Dewey K.G., Harjunmaa U., et al. The impact of lipid-based nutrient supplement provision to pregnant women on newborn size in rural Malawi: A randomized controlled trial. Amer J Clin Nutr 2015;101:387-97.
- 35. Hambidge K.M., Westcott J.E., Garces A., Figueroa L., Goudar S.S., Dhaded S.M., et al. A multicountry randomized controlled trial of comprehensive maternal nutrition supplementation initiated before conception: The Women First trial. Amer J Clin Nutr 2019;109:457-69.
- 36. Kaestel P., Michaelsen K.F., Aaby P., Friis H. Effects of prenatal multimicronutrient supplements on birth weight and perinatal mortality: a randomised, controlled trial in Guinea-Bissau. Eur J Clin Nutr 2005;59:1081-9.
- 37. The Multiple Micronutrient Supplement Technical Advisory Group (MMS-TAG), The Micronutrient Forum (MNF). Expert consensus on an open-access United Nations International Multiple Micronutrient Antenatal Preparation - multiple micronutrient supplement product specification. Annals New York Acad Sci 2020;1470:3-13.
- 38. Keats E.C., Haider B.A., Tam E., Bhutta Z.A. Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev 2019;3:CD004905.
- 39. Wessells K.R., Arnold C.D., Stewart C.P., Prado E.L., Abbeddou S., Adu-Afarwuah S., et al. Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials. Amer J Clin Nutr 2021;114:68S-94S.
- 40. Moore S.E. Sex differences in growth and neurocognitive development in infancy and early childhood. Proc Nutr Soc 2024:1-8.
- 41. Wells J.C. Natural selection and sex differences in morbidity and mortality in early life. J Theor Biol 2000;202:65-76.
- 42. Sauder M.W., Lee S.E., Schulze K.J., Christian P., Wu L.S.F., Khatry S.K., et al. Inflammation throughout pregnancy and fetal growth restriction in rural Nepal. Epidemiol Infect 2019;147:e258.

- 43. Desai M., ter Kuile F.O., Nosten F., McGready R., Asamoa K., Brabin B., Newman R.D. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007;7:93-104.
- 44. Adu-Afarwuah S., Lartey A., Okronipa H., Ashorn P., Zeilani M., Baldiviez L.M., et al. Impact of small-quantity lipid-based nutrient supplement on hemoglobin, iron status and biomarkers of inflammation in pregnant Ghanaian women. Matern Child Nutr 2017;13.
- 45. Jorgensen J.M., Ashorn P., Ashorn U., Baldiviez L.M., Gondwe A., Maleta K., et al. Effects of lipid-based nutrient supplements or multiple micronutrient supplements compared with iron and folic acid supplements during pregnancy on maternal haemoglobin and iron status. Matern Child Nutr 2018;14:e12640.
- 46. Matias S.L., Mridha M.K., Young R.T., Hussain S., Dewey K.G. Daily maternal lipid-based nutrient supplementation with 20 mg iron, compared with iron and folic acid with 60 mg iron, resulted in lower iron status in late pregnancy but not at 6 months postpartum in either the mothers or their infants in Bangladesh. J Nutr 2018;148:1615-24.
- 47. Oaks B.M., Jorgensen J.M., Baldiviez L.M., Adu-Afarwuah S., Maleta K., Okronipa H., et al. Prenatal Iron Deficiency and Replete Iron Status Are Associated with Adverse Birth Outcomes, but Associations Differ in Ghana and Malawi. J Nutr 2019;149:513-21.
- 48. Martinat M., Rossitto M., Di Miceli M., Laye S. Perinatal Dietary Polyunsaturated Fatty Acids in Brain Development, Role in Neurodevelopmental Disorders. Nutrients 2021;13.
- 49. Devakumar D., Fall C.H., Sachdev H.S., Margetts B.M., Osmond C., Wells J.C., et al. Maternal antenatal multiple micronutrient supplementation for long-term health benefits in children: a systematic review and meta-analysis. BMC Med 2016;14:90.
- 50. Mertens A., Benjamin-Chung J., Colford J.M., Jr., Coyle J., van der Laan M.J., Hubbard A.E., et al. Causes and consequences of child growth faltering in low-resource settings. Nature 2023;621:568-76.
- 51. Mahmud I., Guesdon B., Kerac M., Grijalva-Eternod C.S. Mortality risk in infants receiving therapeutic care for malnutrition: A secondary analysis. Matern Child Nutr 2024:e13635.
- 52. McDonald C.M., Olofin I., Flaxman S., Fawzi W.W., Spiegelman D., Caulfield L.E., et al. The effect of multiple anthropometric deficits on child mortality: meta-analysis of individual data in 10 prospective studies from developing countries. Am J Clin Nutr 2013;97:896-901.
- 53. Verney A.M.J., Busch-Hallen J.F., Walters D.D., Rowe S.N., Kurzawa Z.A., Arabi M. Multiple micronutrient supplementation cost-benefit tool for informing maternal nutrition policy and investment decisions. Matern Child Nutr 2023;19:e13523.
- 54. Healthy Mothers Healthy Babies. Multiple Micronutrient Supplementation. Available at: https://hmhbconsortium.org/mms/. Accessed on: 18 March 2024.
- 55. Kumordzie S.M., Adu-Afarwuah S., Arimond M., Young R.R., Adom T., Boatin R., et al. Maternal and infant lipid-based nutritional supplementation increases height of Ghanaian children at 4-6 years only if the mother was not overweight before conception. J Nutr 2019;149:847-55.
- 56. Bentil H.J., Adu-Afarwuah S., Prado E.L., Arnold C.D., Hastings P.D., Guyer A.E., et al. Sustained effects of small-quantity lipid-based nutrient supplements provided during the first 1000 days on child growth at 9-11 y in a randomized controlled trial in Ghana. Am J Clin Nutr 2024;119:425-32.
- 57. WHO. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva, 2016.

- 58. McDonald C.M., Wessells K.R., Stewart C.P., Dewey K.G., de Pee S., Rana R., et al. Antenatal interevention strategies providing food or cash with micronutrients to pregnant and breastfeeding women in low- and middle-income countries: a scoping review. Matern Child Nutr 2024, in submission.
- 59. International Classification of Disease 10th Revision (ICD-10). 2010. Available online at: http://www.who.int/classifications/icd/ICD10Volume2\_en\_2010.pdf?ua-1. Accessed on: 14 June 2021.
- 60. WHO, UNICEF Joint Monitoring Programme. Sanitation. Available at http://washdata.org/monitoring/sanitation. Accessed on: 26 August 2019.

#### **Box 1: Outcome variables**<sup>1</sup>

Continuous outcomes	Categorical outcomes
Birth size and duration of gestation	
Birth weight (g), weight-for-age z score (WAZ)	Low birth weight (LBW) < 2500 g (59), Birth weight < 2000 g
Weight-for-gestational age z-score (WGAZ)	Small-for-gestational age (SGA) < 10 <sup>th</sup> percentile (24)
	Large-for-gestational age (LGA) $> 90^{\text{th}}$ percentile (24)
Birth length (cm), length-for-age z score (LAZ)	Newborn stunting, $LAZ < -2$ SD (22)
Length-for-gestational age z-score (LGAZ)	Low LGAZ (LGAZ $< -2$ SD) (24)
BMI-for-age z-score (BMIZ) <sup>2</sup>	Newborn wasting, BMIZ < -2 SD (22)
Birth head circumference (cm), head circumference-for-age z score (HCZ)	Small head circumference, HCZ < -2 SD (23)
Head circumference-for-gestational age z score (HCGAZ)	Low HCGAZ, HCGAZ $< -2$ SD (2)
Mid-upper arm circumference (MUAC, cm)	
Duration of gestation (wk)	Preterm birth (duration of gestation < 37 wk)
Anthropometric outcomes at 6 months of age	
Weight-for-age Z score (WAZ)	Underweight, WAZ < -2 SD (22)
Length-for-age Z score (LAZ)	Stunting, LAZ < -2 SD (22)
Weight-for-length Z score (WLZ)	Wasting, $WLZ < -2$ SD (22)
Head circumference-for-age Z score (HCZ)	Small head circumference, HCZ < -2 SD (23)
MUAC-for-age Z score (MUACZ)	Low MUAC, MUACZ < -2 SD or MUAC < 125 mm (23)
	Acute malnutrition, WLZ < -2 SD or MUAC < 125 mm (22)
Adverse outcomes	
	Cesarian-section
	Miscarriage, embryo or fetal death < 28 weeks (59)
	Stillbirth, fetal death $\geq$ 28 weeks gestation (59)
	Early neonatal mortality $\leq 7$ days (59)
	Neonatal mortality $\leq$ 28 days (59)
	Infant mortality $< 6$ months

<sup>1</sup> BMIZ, BMI-for-age z-score; HCGAZ, head circumference-for-gestational age z-score; HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LBW, low birth weight; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; MUAC, mid-upper arm circumference; MUACZ, mid-upper arm circumference-for-age z-score; SGA, small-for-gestational age; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score; WLZ, weight-for-length z-score

<sup>2</sup> BMIZ is used as a proxy for weight-for-length z-score because the latter is not calculated for children with lengths < 45 cm (22).

#### **Box 2: Potential effect modifiers**<sup>1</sup>

#### Individual-level child, maternal and household effect modifiers

#### Child

- Sex (female vs. male)
- Birth order (first born vs. later born)

Maternal

- Maternal height (< 150.1 cm vs.  $\ge$  150.1 cm)<sup>2</sup>
- Maternal BMI ( $< 20 \text{ kg/m}^2 \text{ vs.} \ge 20 \text{ kg/m}^2$ )<sup>3</sup>
- Maternal age (< 25 y vs.  $\geq$  25 y)
- Maternal education (no formal or incomplete primary vs. complete primary or greater)
- Baseline anemia status (Hb  $\geq$  110 g/L vs. < 110 g/L)
- Baseline inflammation status (CRP  $\leq$  5 mg/L and AGP  $\leq$  1 g/L vs. not)
- Baseline malaria status (positive rapid test for malaria vs. negative test)
- Gestational age at start of supplementation (< 14 wk vs.  $\geq$  14 wk)
- Compliance with supplementation ( $\geq 4 \text{ d/wk vs.} < 4 \text{ d/wk}$ )<sup>4</sup>

Household

- Household socio-economic status (< study median vs.  $\geq$  study median)<sup>5</sup>
- Household food security (moderate to severe food insecurity vs. mild to secure)
- Sanitation (unimproved vs. improved)<sup>6</sup>

<sup>1</sup>Comparisons follow the format nonreference vs. reference category. AGP,  $\alpha$ -1-acid glycoprotein; CRP, C-reactive protein; Hb, hemoglobin. Some potential effect modifiers that were listed in the statistical analysis plan were not included: maternal marital status was dropped because of insufficient variation; maternal depression was dropped because it was evaluated only at 6 mo postpartum; source water quality was not included because there was little variation in two of the eligible trials; season at time of conception was not included because the seasonal factors that may influence pregnancy outcomes (rainy/dry, harvest/hungry, heat stress) do not always coincide and a 9-month pregnancy involves exposure to several seasons at different stages of pregnancy.

<sup>2</sup>Cutoff is -2 SD for height at 19 years of age: <u>https://www.who.int/growthref/hfa\_girls\_5\_19years\_z.pdf?ua=1</u>

<sup>3</sup>When a pre-pregnancy weight measurement was not available, we estimated weight back to the 9th week of gestation using a restricted cubic spline model regressing baseline weight on gestational age at enrollment with 4 knots based on quintiles in the study's full dataset.

<sup>4</sup>Cutoff of > 4 d/wk chosen to accommodate the categorical variable for compliance used in the Bangladesh trial (32), which had only these choices: "did not take at all," "used to take sometimes (1-3 d/wk)," "used to take almost every day (4–6 d/wk)," "used to take regularly every day," and "other."

<sup>5</sup>Based on a study-defined, study-specific assets index

<sup>6</sup>Improved sanitation includes flush/pour flush to piped sewer system, septic tanks or pit latrines; ventilated improved pit latrines, composting toilets or pit latrines with slabs (60); see Supplemental Table 2, based on baseline data

Country,	Maternal Intervention Groups	Comp	arisons		Maternal C	haracteristics	at enrollment	
years of study, study name, N, trial design, (author date)		SQ- LNS vs. control	SQ- LNS vs. MMS	Gestationa l age (wk)	Maternal age (y)	Maternal pre- pregnancy BMI (kg/m <sup>2</sup> )	Nulliparous (%)	Moderately or severely food insecure (%)
Bangladesh, 2011-2015, RDNS, N=4011,	SQ-LNS from $\leq 20$ weeks gestation to 6 mo post-partum	~		12 1 (2 0)	22.0.(5.0)		20.7	20.2
cluster RCT; longitudinal follow-up (Mridha 2016) (32)	IFA from $\leq 20$ weeks gestation to 3 mo post-partum <sup>2</sup>	~		13.1 (3.8)	22.0 (5.0)	20.1 (2.7)	39.7	38.2
Ghana, 2009-2014,	SQ-LNS from $\leq$ 20 weeks gestation to 6 mo post-partum	~	~					
iLiNS-DYAD-G, N=1320, RCT; longitudinal follow-up (Adu-Afarwuah 2015) (33)	IFA from $\leq 20$ weeks gestation to delivery, low-dose Ca from delivery to 6 mo post-partum	~		16.2 (3.3)	26.5 (5.3)	23.9 (4.3)	36.8	29.7
	MMS from $\leq$ 20 weeks gestation to 6 mo post-partum		~					
Malawi, 2011-2014,	SQ-LNS from $\leq 20$ weeks gestation to 6 mo post-partum <sup>4</sup>	~	~					
iLiNS-DYAD-M, N= 1391 <sup>3</sup> , RCT, longitudinal follow-up (Ashorn 2015) (34)	IFA from $\leq 20$ weeks gestation to delivery, low-dose Ca from delivery to 6 mo post-partum <sup>4</sup>	~		16.8 (2.1)	25.1 (6.2)	20.5 (2.7)	20.6	66.2
	MMS from $\leq 20$ weeks gestation to 6 mo post-partum <sup>4</sup>		~					
Guatemala, 2013 - 2017	SQ-LNS from $\geq$ 3 months pre- conception to delivery	<b>(</b> ✓ <b>)</b> <sup>7</sup>						
Women First <sup>5</sup> , N = 1808 <sup>6</sup> RCT, longitudinal follow-up	SQ-LNS from start of 2 <sup>nd</sup> trimester (12- 14 weeks) to delivery	~		11.9 (2.0)	24.4 (4.3)	25.4 (4.1)	6.3	-
(Hambidge 2019) (35)	standard of care (SOC)	~						

#### Table 1. Characteristics of trials included in the individual participant data analysis<sup>1</sup>

<sup>1</sup>IFA, iron and folic acid supplements; LNS, lipid-based nutrient supplements; MMS, multiple micronutrient supplements; SQ-LNS, small-quantity lipid-based nutrient supplement; RCT, randomized controlled trial

<sup>2</sup>In 3 study arms of the RDNS trial, women received IFA during pregnancy and for 3 months post-partum (these study arms differed in that index children received one of 3 different child supplements from 6-24 months); for the purpose of these analyses, these study arms were combined and compared with the maternal SQ-LNS arm.

<sup>3</sup>Total number enrolled in Malawi was 1391. 869 women were assigned to the complete intervention and 18-month follow-up. 522 women were assigned to pregnancy supplementation only, with simplified follow-up.

<sup>4</sup>Interventions noted in the table were provided to women assigned to the complete intervention cohort. Women in the simplified follow-up received supplements (SQ-LNS, IFA or MMS) from  $\leq$  20 weeks of gestation to delivery only.

<sup>5</sup>The Women First trial provided a protein-energy supplement (in addition to SQ-LNS) to enrolled women who were either underweight or who had inadequate gestational weight gain. In 3 of the 4 study sites (Democratic Republic of the Congo, India, and Pakistan), >90% of enrolled women received this supplement in addition to SQ-LNS. Therefore, only the Guatemala site is included in these analyses (where < 10% of enrolled women received a protein-energy supplement in addition to SQ-LNS).

<sup>6</sup>Total number enrolled (prior to conception) was 1808 in Guatemala; the number of live births for data analysis was 651 (193 in the preconception arm, 229 in the pregnancy arm, 229 in the SOC arm).

<sup>7</sup>The study arm that provided pre-conception SQ-LNS was excluded from the primary comparisons; results including this arm are presented in supplemental materials.

Birth outcome	Number of participants (trials)	SQ-LNS events per 1000	IFA/SO C events	MD or RR plus difference in events per 1000 (95% CI) <sup>2</sup>	P value <sup>3</sup>	Heterogeneity I <sup>2</sup>	Quality of the evidence
Birth weight (g)	5273 (4)		per 1000	48.7 (26.1, 71.2)	< 0.001	0.00	(GRADE) Moderate
Weight-for-age z score (WAZ)	5273 (4)	-	-	0.12 (0.06, 0.17)	<0.001	0.00	Moderate
Weight-for-gestational age z-score (WGAZ) <sup>4</sup>	1717 (3)	-	-	0.12 (0.05, 0.17)	0.001	0.31	Moderate
Low birth weight (LBW)	5273 (4)	168	198	0.89 (0.80, 0.99) -28.6 (-51.3, -5.9)	0.033 0.013	0.00 0.00	Moderate
Birth weight < 2 kg	5273 (4)	25	35	0.78 (0.60, 1.01) -9.1 (-18.5, 0.2)	0.062 0.054	0.00 0.00	Moderate
Small-for-gestational age (SGA)	5181 (4)	303	335	0.96 (0.92, 1.01) -23.0 (-46.7, 0.7)	0.133 0.057	0.00 0.00	Moderate
Large-for-gestational age (LGA)	4834 (3)	20	23	1.00 (0.61, 1.65) 1.1 (-3.1, 5.3)	0.984 0.611	0.00 0.00	Moderate
Birth length (cm)	5014 (4)	-	-	0.20 (0.09, 0.31)	< 0.001	0.00	Moderate
Length-for-age z score (LAZ)	5014 (4)	-	-	0.11 (0.06, 0.17)	< 0.001	0.00	Moderate
Length-for-gestational age z-score (LGAZ) <sup>4</sup>	1460 (3)	-	-	0.13 (0.05, 0.21)	0.002	0.00	Moderate
Newborn stunting	5014 (4)	138	164	0.83 (0.74, 0.93) -32.2 (-51.5, -12.9)	0.001 0.001	0.00 0.00	Moderate
Low LGAZ	4922 (4)	118	127	0.90 (0.80, 1.01) -12.0 (-29.6, 5.6)	0.082 0.182	0.00 0.00	Moderate
BMI-for-age z-score (BMIZ)	5002 (4)	-	-	0.10 (0.04, 0.16)	0.002	0.00	Moderate
Low BMIZ	5002 (4)	123	145	0.89 (0.81, 0.98) -23.6 (-42.7, -4.5)	0.022 0.015	0.26 0.20	Moderate
Head circumference (cm)	5016 (4)	-	-	0.11 (0.04, 0.18)	0.002	0.00	Moderate
Head circumference-for-age z-score (HCZ)	5016 (4)	-	-	0.10 (0.04, 0.16)	0.001	0.00	Moderate
Head circumference-for-gestational age z-score (HCGAZ) <sup>4</sup>	1461 (3)	-	-	0.11 (0.02, 0.20)	0.019	0.00	Moderate
Low HCZ	5016 (4)	100	118	0.85 (0.75, 0.96) -22.1 (-40.5, -3.7)	0.009 0.019	0.00 0.00	Moderate

## Table 2. Main effects of maternal SQ-LNS vs IFA/SOC on birth outcomes<sup>1</sup>

Low HCGAZ	4924 (4)	54	64	0.88 (0.76, 1.01)	0.072	0.00	Moderate
				-6.4 (-18.4, 5.5)	0.291	0.32	
Mid-upper arm circumference	4581 (3)	-	-	0.08 (0.02, 0.14)	0.009	0.00	Moderate
(MUAC) (cm) Duration of gestation (wk)	5348 (4)			0.12 (0.01, 0.24)	0.040	0.00	Moderate
Preterm birth	5348 (4)	106	- 111	0.12 (0.01, 0.24)	0.040	0.00	Moderate
	55-10 (1)	100	111	-7.1 (-25.8, 11.5)	0.454	0.00	Wioderate

<sup>1</sup>BMIZ, BMI-for-age z-score; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCGAZ, head circumference-for-gestational age z-score; HCZ, head circumference-for-age z-score; IFA, iron and folic acid supplement; LAZ, length-for-age z-score; LBW, low birth weight; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; MD, mean difference; MUAC, mid-upper arum circumference; RR, relative risk; SGA, small-for-gestational age; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score

<sup>2</sup>For continuous outcomes, values are MDs: LNS – IFA/SOC (95% CIs). For binary outcomes, values are RRs: LNS compared with IFA/SOC (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

<sup>3</sup>The P value column corresponds to the pooled main effect 2-sided superiority testing of the intervention effect estimate and 95% CI presented in the preceding column.  $I^2$  describes the percentage of variability in effect estimates that may be due to heterogeneity rather than chance. Roughly, 0.3 - 0.6 may be considered moderate heterogeneity.

<sup>4</sup> For continuous outcomes based on INTERGROWTH-21st standards, we excluded participants without ultrasound data for calculation of gestational age. For the corresponding binary outcomes (SGA, LGA, Low LGAZ, Low HCGAZ), we retained participants without ultrasound dating but conducted a sensitivity analysis in which they were excluded.

Infant anthropometric outcomes at 6 mo	Number of participants (trials)	SQ-LNS events per 1000	IFA/SOC events per 1000	MD or PR plus difference in events per 1000 (95% CI) <sup>2</sup>	P value <sup>3</sup>	Heterogeneity I <sup>2</sup>	Quality of the evidence (GRADE)
Weight-for-age z-score (WAZ)	5029 (4)	-	-	0.05 (-0.02, 0.13)	0.173	0.00	Moderate
Underweight	5029 (4)	114	132	0.85 (0.73, 0.99) -22.1 (-41.8, -2.5)	0.041 0.027	0.41 0.37	Moderate
Length-for-age z-score (LAZ)	5032 (4)	-	-	0.06 (-0.01, 0.13)	0.080	0.02	Moderate
Stunted	5032 (4)	198	219	0.90 (0.80, 1.02) -17.4 (-43.3, 8.5)	0.102 0.187	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Moderate
Weight-for-length z-score (WLZ)	5028 (4)	-	-	0.00 (-0.07, 0.07)	0.969	0.00	Moderate
Wasted	5028 (4)	24	32	0.91 (0.66, 1.25) -6.3 (-15.8, 3.1)	0.558 0.191	0.39 0.36	Moderate
Head circumference-for-age z-score (HCZ)	5028 (4)	-	-	0.01 (-0.05, 0.07)	0.679	0.00	Moderate
Low HCZ	5028 (4)	110	125	0.90 (0.80, 1.02) -13.2 (-31.9, 5.4)	0.098 0.164	0.00 0.00	Moderate
MUAC-for-age z-score (MUACZ)	4600 (3)	-	-	0.00 (-0.07, 0.08)	0.949	0.00	Moderate
Low MUAC [MUACZ < -2 SD or MUAC < 125 mm]	4600 (3)	68	64	1.00 (0.78, 1.29) -0.1 (-17.9, 17.7)	0.970 0.993	0.00 0.00	Moderate
Acute malnutrition [WLZ < -2 SD or MUAC < 125 mm]	4595 (3)	80	82	1.00 (0.79, 1.25) -0.7 (-19.4, 17.9)	0.970 0.938	0.00 0.00	Moderate

#### Table 3. Main effects of maternal SQ-LNS vs IFA/SOC on infant anthropometric outcomes at 6 mo of age<sup>1</sup>

<sup>1</sup>GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCZ, head circumference-for-age z-score; IFA, iron and folic acid supplement; LAZ, length-for-age z-score; MD, mean difference; MUAC, mid-upper arum circumference; MUACZ, mid-upper arm circumference-for-age z-score; PR, prevalence ratio; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score<sup>2</sup>For continuous outcomes, values are MDs: LNS – IFA/SOC (95% CIs). For binary outcomes, values are PRs: LNS compared with IFA/SOC (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

Adverse outcomes	Number of participants (trials)	SQ-LNS events per 1000	IFA/SOC events per 1000	RR and difference in events per 1000 (95% CI) <sup>2</sup>	P value <sup>3</sup>	Heterogeneity I <sup>2</sup>	Quality of the evidence (GRADE)
Cesarian-Section	5693 (4)	167	156	1.04 (0.90, 1.19) 18.6 (-3.6, 40.9)	0.595 0.101	0.42 0.01	Moderate
Miscarriage	6102 (4)	49	59	0.87 (0.70, 1.08) 0.7 (-7.1, 8.6)	0.213 0.852	0.00 0.27	Moderate
Stillbirth	6102 (4)	24	18	1.31 (0.90, 1.91) 7.1 (-1.7, 15.9)	0.153 0.116	0.49 0.53	Moderate
Miscarriage or stillbirth	6102 (4)	75	77	0.98 (0.81, 1.19) 1.4 (-12.3, 15.1)	$\begin{array}{c} 0.870\\ 0.844 \end{array}$	0.39 0.40	Moderate
Early neonatal mortality	5506 (4)	14	20	0.74 (0.46, 1.19) -4.8 (-13.2, 3.7)	0.208 0.272	0.04 0.22	Moderate
Miscarriage or stillbirth or early neonatal mortality	6102 (4)	89	97	0.93 (0.77, 1.12) -6.6 (-23.4, 10.3)	0.452 0.444	0.00 0.00	Moderate
Neonatal mortality	5528 (4)	21	25	0.83 (0.56, 1.24) -2.9 (-12.3, 6.6)	0.360 0.551	0.00 0.10	Moderate
Mortality 0-6 mo	5566 (4)	30	32	0.95 (0.69, 1.30) -0.6 (-11.0, 9.8)	0.739 0.913	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Moderate

#### Table 4. Main effects of maternal SQ-LNS vs IFA/SOC on adverse outcomes<sup>1</sup>

<sup>1</sup>GRADE, Grading of Recommendations Assessment, Development and Evaluation; IFA, iron and folic acid supplement; RR, relative risk; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplement

<sup>2</sup>Values are RRs: LNS compared with IFA/SOC (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

Birth outcome	Number of participants (trials)	SQ-LNS events per 1000	MMS events per 1000	MD or RR plus difference in events per 1000 (95% CI) <sup>2</sup>	P value <sup>3</sup>	Heterogeneity I <sup>2</sup>	Quality of the evidence (GRADE)
Birth weight (g)	1391 (2)	-	-	27.8 (-19.1, 74.6)	0.245	0.00	Low
Weight-for-age z score (WAZ)	1391 (2)	-	-	0.06 (-0.05, 0.17)	0.263	0.00	Low
Weight-for-gestational age z-score (WGAZ)	1377 (2)	-	-	0.06 (-0.05, 0.16)	0.294	0.00	Low
Low birth weight (LBW)	1391 (2)	105	119	0.88 (0.66, 1.18) -14.2 (-47.3, 18.8)	0.397 0.399	0.00 0.00	Low
Birth weight < 2 kg	1391 (2)	19	19	$\begin{array}{c} -14.2 & (-47.3, 10.3) \\ \hline 1.07 & (0.52, 2.23) \\ -1.1 & (-15.1, 12.9) \end{array}$	0.850 0.877	0.00	Low
Small-for-gestational age (SGA)	1391 (2)	214	224	0.96 (0.79, 1.17) -9.3 (-52.7, 34.2)	0.717 0.677	0.00 0.00	Low
Large-for-gestational age (LGA)	1391 (2)	32	28	1.16 (0.64, 2.10) 5.2 (-12.6, 23.1)	0.622 0.564	0.00	Low
Birth length (cm)	1137 (2)	_	-	0.16 (-0.09, 0.40)	0.209	0.00	Low
Length-for-age z score (LAZ)	1137 (2)	-	-	0.07 (-0.05, 0.20)	0.247	0.00	Low
Length-for-gestational age z-score (LGAZ)	1123 (2)	-	-	0.08 (-0.04, 0.20)	0.214	0.00	Low
Newborn stunting	1137 (2)	118	110	1.06 (0.77, 1.47) 5.5 (-31.3, 42.3)	0.710 0.770	0.00 0.00	Low
Low LGAZ	1137 (2)	109	88	1.22 (0.85, 1.74) 11.8 (-19.6, 43.2)	0.276 0.463	0.00 0.01	Low
BMI-for-age z-score (BMIZ)	1121 (2)	_	-	0.01 (-0.12, 0.14)	0.830	0.00	Low
Low BMIZ	1121 (2)	67	68	0.99 (0.64, 1.53) -1.2 (-30.8, 28.5)	0.964 0.939	0.30 0.30	Low
Head circumference (cm)	1138 (2)	_	_	0.14 (-0.02, 0.31)	0.088	0.08	Low
Head circumference-for-age z-score (HCZ)	1138 (2)	_	-	0.11 (-0.02, 0.24)	0.109	0.00	Low
Head circumference-for-gestational age z- score (HCGAZ)	1124 (2)	-	-	0.11 (-0.01, 0.23)	0.066	0.00	Low
Low HCZ	1138 (2)	56	43	1.27 (0.77, 2.10) 12.3 (-13.0, 37.6)	0.352 0.341	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low
Low HCGAZ	1138 (2)	16	17	0.85 (0.35, 2.05) -1.6 (-16.6, 13.4)	0.711 0.831	0.00 0.00	Low
Mid-upper arm circumference (MUAC) (cm)	1142 (2)	-	-	0.08 (-0.02, 0.18)	0.127	0.00	Low
Duration of gestation (wk)	1539 (2)	-	-	-0.04 (-0.27, 0.20)	0.771	0.00	Low

Preterm birth	1539 (2)	99	79	1.21 (0.88, 1.66)	0.244	0.00	Low
				18.4 (-10.2, 47.0)	0.206	0.00	

<sup>1</sup>BMIZ, BMI-for-age z-score; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCGAZ, head circumference-for-gestational age z-score; HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LBW, low birth weight; LGA, large-for-gestational age; LGAZ, length-for-gestational age z-score; MD, mean difference; MMS, multiple micronutrient supplements; MUAC, mid-upper arum circumference; RR, relative risk; SGA, small-for-gestational age; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WGAZ, weight-for-gestational age z-score

<sup>2</sup>For continuous outcomes, values are MDs: LNS – MMS (95% CIs). For binary outcomes, values are RRs: LNS compared with MMS (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

Infant anthropometric outcomes at 6 mo	Number of participants (trials)	SQ-LNS events per 1000	MMS events per 1000	MD or PR plus difference in events per 1000 (95% CI) <sup>2</sup>	P value <sup>3</sup>	Heterogeneity I <sup>2</sup>	Quality of the evidence (GRADE)
Weight-for-age z-score (WAZ)	1292 (2)	-	-	-0.01 (-0.14, 0.11)	0.827	0.00	Low
Underweight	1292 (2)	85	75	1.13 (0.78, 1.64) 9.5 (-20.2, 39.2)	0.510 0.531	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low
Length-for-age z-score (LAZ)	1289 (2)	-	-	0.02 (-0.10, 0.13)	0.792	0.00	Low
Stunted	1289 (2)	166	155	1.05 (0.83, 1.34) 13.7 (-25.0, 52.5)	0.673 0.487	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low
Weight-for-length z-score (WLZ)	1288 (2)	-	-	-0.04 (-0.16, 0.09)	0.551	0.00	Low
Wasted	1288 (2)	24	23	0.97 (0.48, 1.97) 0.2 (-16.4, 16.9)	0.943 0.977	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low
Head circumference-for-age z-score (HCZ)	1293 (2)	-	-	-0.03 (-0.13, 0.08)	0.636	0.00	Low
Low HCZ	1293 (2)	63	81	0.77 (0.52, 1.15) -18.0 (-46.2, 10.2)	0.203 0.211	0.00 0.00	Low
MUAC-for-age z-score (MUACZ)	1293 (2)	-	-	-0.02 (-0.14, 0.10)	0.727	0.00	Low
Low MUACZ [MUACZ < -2 SD or MUAC < 125 mm]	1293 (2)	66	74	0.92 (0.62, 1.36) -6.8 (-34.6, 21.1)	0.672 0.633	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low
Acute malnutrition [WLZ < -2 SD or MUAC < 125 mm]	1288 (2)	75	77	0.98 (0.67, 1.43) -1.9 (-31.0, 27.2)	0.918 0.899	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low

Table 6. Main effects of maternal SQ-LNS vs MMS on infant anthropometric outcomes at 6 mo of age<sup>1</sup>

<sup>1</sup>GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCZ, head circumference-for-age z-score; LAZ, length-forage z-score; MD, mean difference; MUAC, mid-upper arum circumference; MMS, multiple micronutrient supplements; MUACZ, mid-upper arm circumference-for-age z-score; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplement; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score

<sup>2</sup>For continuous outcomes, values are MDs: LNS – MMS (95% CIs). For binary outcomes, values are PRs: LNS compared with MMS (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

Adverse outcomes	Number of participants (trials)	SQ-LNS events per 1000	MMS events per 1000	RR and difference in events per 1000 (95% CI) <sup>2</sup>	P value <sup>3</sup>	Heterogeneity I <sup>2</sup>	Quality of the evidence (GRADE)
Cesarian-Section	1491 (2)	129	103	1.25 (0.94, 1.66) 27.0 (-2.1, 56.2)	0.125 0.069	0.00 0.00	Low
Miscarriage	1566 (2)	16	16	1.00 (0.47, 2.13) -0.1 (-11.3, 11.2)	0.994 0.991	$\begin{array}{c} 0.00\\ 0.00\end{array}$	Low
Stillbirth	1566 (2)	21	11	1.57 (0.61, 4.03) 9.9 (-2.9, 22.7)	0.344 0.129	0.85 0.87	Low
Miscarriage or stillbirth	1566 (2)	39	28	1.33 (0.76, 2.34) 14.7 (-2.9, 32.2)	0.320 0.102	0.79 0.73	Low
Early neonatal mortality	1470 (2)	19	17	0.96 (0.44, 2.09) 4.0 (-9.1, 17.2)	0.924 0.550	0.61 0.59	Low
Miscarriage or stillbirth or early neonatal mortality	1566 (2)	57	46	1.24 (0.81, 1.91) 11.3 (-10.7, 33.3)	0.321 0.313	0.00 0.00	Low
Neonatal mortality	1473 (2)	23	19	1.05 (0.52, 2.10) 4.5 (-9.9, 19.0)	0.896 0.537	0.47 0.38	Low
Mortality 0-6 mo	1483 (2)	30	28	1.00 (0.56, 1.78) 4.6 (-11.7, 20.9)	0.988 0.584	0.43 0.33	Low

<sup>1</sup>GRADE, Grading of Recommendations Assessment, Development and Evaluation; MMS, multiple micronutrient supplement; RR, relative risk; SQ-LNS, small-quantity lipid-based nutrient supplement

<sup>2</sup>Values are RRs: LNS compared with MMS (95% CIs). Difference in events per 1000 was calculated using the prevalence difference (95% CI) and multiplying by 1000.

#### **Figure Legends**

Figure 1: Study flow diagram. IFA, iron and folic acid supplements; IPD, individual participant data; MMS, multiple micronutrient supplements; RCT, randomized controlled trial; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplements.


Figures 2A-F: Forest plots of effect of SQ-LNS vs IFA/SOC on birth weight, LBW, newborn LAZ, newborn HCZ, newborn BMIZ and duration of gestation. BMIZ, body mass index z-score; HCZ, head circumference-for-age z-score; IFA, iron and folic acid; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplements; LBW, low birthweight; MD, mean difference; RR, relative risk; SOC, standard of care; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates were generated using inverse-variance weighting with both fixed and random effects.

Figures 3A-J: Pooled effects of SQ-LNS vs IFA/SOC on birth outcomes, stratified by selected effect modifiers. LNS, lipid-based nutrient supplements; P-for-interaction, p-value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates (not shown) were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates (shown here) were generated using inverse-variance weighting with fixed effects.

53

Figures 4A,B: Pooled effects of SQ-LNS vs IFA/SOC on anthropometric outcomes at 6 mo of age, stratified by infant sex. LNS, lipid-based nutrient supplements; P-for-interaction, p-value for the interaction indicating the difference in effects of SQ-LNS between the two levels of the effect modifier; PR, prevalence ratio; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates (not shown) were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates (shown here) were generated using inverse-variance weighting with fixed effects.

Figures 5A-C: Forest plots of effect of SQ-LNS vs MMS on birth weight, newborn LAZ, and newborn HCZ. HCZ, head circumference-for-age z-score; LAZ, length-for-age z-score; LNS, lipid-based nutrient supplements; MD, mean difference; MMS, multiple micronutrient supplements; SQ-LNS, small-quantity lipid-based nutrient supplements. Individual study estimates were generated from log-binomial regression for binary outcomes and linear regression for continuous outcomes controlling for baseline measure when available and using robust standard errors for cluster-randomized trials. Pooled estimates were generated using inversevariance weighting with both fixed and random effects.



**Birth weight** SQ-LNS IFA/SOC MD (95% CI) Ν Ν Trial DYAD-G 307 305 80 (12, 148) 0.11 0.11 DYAD-M 387 386 48 (-16, 112) 0.12 0.12 Bangladesh RDNS 898 2551 41 (11, 71) 0.55 0.55 WOMEN FIRST 223 216 53 (4, 101) 0.21 0.21  $l^2 = 0.00$ , Tau<sup>2</sup> = 0.00 1815 3458 49 (26, 71)

Random

Fixed

Country

Ghana


Malawi

Guatemala

-150 0 medRxiv preprint doi: https://doi.org/10.1101/2024.05.17.24307546; this version posted May 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Favors SQ-LNS


3334

Newborn LAZ




 $l^2 = 0.00$ , Tau<sup>2</sup> = 0.00 1680 Fixed

Random




Newborn BMIZ



E)

C)



-0.5

Favors IFA/SOC

0

Difference

D)

F)

B)

**Fixed Random** 

W

**Fixed Random** 

W

49 (26, 71)

150

MD

	Fixed	Random
	W	W
)	0.05	0.05
)	0.08	0.08
)	0.78	0.78
)	0.09	0.09

	Fixed	Random
	W	W
	0.10	0.10
)	0.09	0.09
	0.62	0.62
)	0.19	0.19

**Fixed Random** W W

0.5

Favors SQ-LNS

A) Sex

# Birth outcomes stratified by selected effect modifiers, SQ-LNS vs IFA/SOC B) Sex

Outcome	SQ-LN	S IFA/SOC		Mean difference	Outcome	SQ-LN	S IFA/SOC		Relative risk
(p-for-interaction)	Ν	Ν		(95% CI)	(p-for-interaction)	Ν	Ν		(95% CI)
Weight (kg) (p=0.017)					Low birth weight (p=0.016)				
Male	901	1736	┟╼┤	0.03 (-0.01, 0.06)	Male	901	1736	┝╌┳╌┤	1.01 (0.86, 1.18)
Female	914	1722	<b>⊦</b> ∎-1	0.08 (0.05, 0.11)	Female	914	1722	┝╼╾┥	0.80 (0.71, 0.90)
Length-for-age z-score (p=0.139)					Birth weight < 2 kg (p=0.01	8)			
Male	831	1677	ŀ <b>├──</b> ──┤	0.07 (-0.02, 0.16)	Male	797	1620	<b>-</b>	<b>H</b> 1.14 (0.79, 1.66)
Female	849	1657	┝╌═╌┤	0.16 (0.09, 0.24)	Female	795	1622 -		0.50 (0.30, 0.84)
BMI z-score (p=0.025)					Newborn stunting (p=0.332	2)			
Male	829	1670	⊦_ <mark>_</mark> ∎ł	0.03 (-0.06, 0.12)	Male	831	1677	┝──╋──┤	0.88 (0.74, 1.06)
Female	847	1656	┝╌═╌┤	0.17 (0.09, 0.25)	Female	849	1657	┝╌┳╌┤	0.76 (0.64, 0.90)
Head circumference-for-age z-score (p=0.0	073)				SGA (p=0.283)				
Male	832	1678	<b>⊢</b> ,∎,,,	0.05 (-0.04, 0.14)	Male	881	1707	⊦∎-1	0.99 (0.91, 1.06)
Female	848	1658	┝╌═╌┥	0.16 (0.08, 0.24)	Female	892	1701	┝╼┤	0.93 (0.87, 1.00)
MUAC (p=0.193)					Low HCAZ (p=0.848)				
Male	730	1562	┟┼┲╌┨	0.04 (-0.04, 0.13)	Male	832	1678	┝──■──┤	0.86 (0.68, 1.08)
Female	731	1558	<b>├──■</b> ──┤	0.12 (0.04, 0.19)	Female	848	1658	┝╌┳╌┤	0.83 (0.71, 0.96)
Duration (wk) (p=0.003)					Preterm birth (p=0.080)				
Male	918	1748	<b>├───₽</b>	-0.06 (-0.24, 0.13)	Male	918	1748	┝──╋──┤	1.08 (0.86, 1.36)
Female	922	1726		0.30 (0.15, 0.45)	Female	922	1726	<u>}−∎−</u> -	0.82 (0.65, 1.03)
		-0.4	0	0.4				0.50 1.0	2.00
			Difference					Ratio	
C) Maternal BMI		Favors	IFA/SOC Favors SQ	Į-LNS	D) Matamal DMI			Favors SQ-LNS Fav	ors IFA/SOC
C) Maternal BMI					D) Maternal BMI				
Outcome		S IFA/SOC		Mean difference	Outcome		S IFA/SOC		Relative risk
,	SQ-LN N	S IFA/SOC N		Mean difference (95% CI)		SQ-LN N	IS IFA/SOC N		Relative risk (95% Cl)
Outcome		Ν			Outcome	Ν	Ν		
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup>	<b>N</b> 1041	<b>N</b> 1806	+ <b>■</b> -		Outcome (p-for-interaction)	<b>N</b> 1041	<b>N</b> 1806	₽──■┤-1	
Outcome (p-for-interaction) Weight (kg) (p=0.233)	Ν	Ν	<b>⊦</b> ∎-1  +■-1	(95% CI)	Outcome (p-for-interaction) Low birth weight (p=0.248)	Ν	Ν	┞──₩┤─┤ ┠──₩──┤	(95% CI)
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Length-for-age z-score (p=0.303)	<b>N</b> 1041 736	<b>N</b> 1806 1567		(95% CI) 0.04 (0.02, 0.07)	<b>Outcome</b> (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m <sup>2</sup>	<b>N</b> 1041 736 20)	<b>N</b> 1806 1567	• -	<b>(95% CI)</b> 0.93 (0.80, 1.08) 0.87 (0.76, 0.98)
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup>	<b>N</b> 1041	<b>N</b> 1806		(95% CI) 0.04 (0.02, 0.07)	<b>Outcome</b> (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup>	<b>N</b> 1041 736	<b>N</b> 1806	• -	<b>(95% CI)</b> 0.93 (0.80, 1.08)
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Length-for-age z-score (p=0.303)	<b>N</b> 1041 736	<b>N</b> 1806 1567	┝╼┤	(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Birth weight < 2 kg (p=0.22	<b>N</b> 1041 736 20)	<b>N</b> 1806 1567	• -	<b>(95% CI)</b> 0.93 (0.80, 1.08) 0.87 (0.76, 0.98)
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Length-for-age z-score (p=0.303) At least 20 kg/m <sup>2</sup>	<b>N</b> 1041 736 975	<b>N</b> 1806 1567 1749	┝╼┤	(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22 At least 20 kg/m²	N 1041 736 20) 582 671	<b>N</b> 1806 1567 1357	• -	<ul> <li>(95% CI)</li> <li>0.93 (0.80, 1.08)</li> <li>0.87 (0.76, 0.98)</li> <li>→ 1.08 (0.66, 1.78)</li> </ul>
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Length-for-age z-score (p=0.303) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup>	<b>N</b> 1041 736 975	<b>N</b> 1806 1567 1749	┝╼┤	(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22 At least 20 kg/m² Less than 20 kg/m²	N 1041 736 20) 582 671	<b>N</b> 1806 1567 1357	• -	<ul> <li>(95% CI)</li> <li>0.93 (0.80, 1.08)</li> <li>0.87 (0.76, 0.98)</li> <li>→ 1.08 (0.66, 1.78)</li> </ul>
Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Length-for-age z-score (p=0.303) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> BMI z-score (p=0.239)	<b>N</b> 1041 736 975 667	N 1806 1567 1749 1501	+ <b>■</b> -    <b>■</b>	(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22 At least 20 kg/m² Less than 20 kg/m² Newborn stunting (p=0.342	N 1041 736 20) 582 671 2)	N 1806 1567 1357 1502 ⊣	• -	<ul> <li>(95% Cl)</li> <li>0.93 (0.80, 1.08)</li> <li>0.87 (0.76, 0.98)</li> <li>→ 1.08 (0.66, 1.78)</li> <li>0.69 (0.46, 1.02)</li> </ul>
Outcome(p-for-interaction)Weight (kg) (p=0.233)At least 20 kg/m²Less than 20 kg/m²Length-for-age z-score (p=0.303)At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²BMI z-score (p=0.239)At least 20 kg/m²	N 1041 736 975 667 974 664	N 1806 1567 1749 1501 1748	⊦=-; ;=-; ;=-;	(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22 At least 20 kg/m² Less than 20 kg/m² Newborn stunting (p=0.342 At least 20 kg/m²	N 1041 736 20) 582 671 2) 975	N 1806 1567 1357 1502 ⊢ 1749	· - · · · · · · · · · · · · · · · · · ·	<ul> <li>(95% Cl)</li> <li>0.93 (0.80, 1.08)</li> <li>0.87 (0.76, 0.98)</li> <li>→ 1.08 (0.66, 1.78)</li> <li>0.69 (0.46, 1.02)</li> <li>0.89 (0.75, 1.06)</li> </ul>
, Outcome (p-for-interaction) Weight (kg) (p=0.233) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Length-for-age z-score (p=0.303) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> MI z-score (p=0.239) At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup>	N 1041 736 975 667 974 664	N 1806 1567 1749 1501 1748	⊦=-; ;=-; ;=-;	(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22) At least 20 kg/m² Less than 20 kg/m² Newborn stunting (p=0.342) At least 20 kg/m² Less than 20 kg/m²	N 1041 736 20) 582 671 2) 975	N 1806 1567 1357 1502 ⊢ 1749	· - · · · · · · · · · · · · · · · · · ·	<ul> <li>(95% Cl)</li> <li>0.93 (0.80, 1.08)</li> <li>0.87 (0.76, 0.98)</li> <li>→ 1.08 (0.66, 1.78)</li> <li>0.69 (0.46, 1.02)</li> <li>0.89 (0.75, 1.06)</li> </ul>
YOutcome(p-for-interaction)Weight (kg) (p=0.233)At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²Length-for-age z-score (p=0.303)At least 20 kg/m²Less than 20 kg/m²BMI z-score (p=0.239)At least 20 kg/m²Less than 20 kg/m²	N 1041 736 975 667 974 664 185)	N 1806 1567 1749 1501 1748 1494		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22) At least 20 kg/m² Less than 20 kg/m² Newborn stunting (p=0.342) At least 20 kg/m² Less than 20 kg/m² SGA (p=0.923)	N 1041 736 20) 582 671 2) 975 667	N 1806 1567 1357 1502 ⊢ 1749 1501		<ul> <li>(95% Cl)</li> <li>0.93 (0.80, 1.08)</li> <li>0.87 (0.76, 0.98)</li> <li>→ 1.08 (0.66, 1.78)</li> <li>0.69 (0.46, 1.02)</li> <li>0.89 (0.75, 1.06)</li> <li>0.80 (0.69, 0.93)</li> </ul>
yOutcome(p-for-interaction)Weight (kg) (p=0.233)At least 20 kg/m²Less than 20 kg/m²Length-for-age z-score (p=0.303)At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²BMI z-score (p=0.239)At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²Head circumference-for-age z-score (p=0.At least 20 kg/m²	N 1041 736 975 667 974 664 185) 973	N 1806 1567 1749 1501 1748 1494 1751		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22) At least 20 kg/m² Less than 20 kg/m² Newborn stunting (p=0.342) At least 20 kg/m² Less than 20 kg/m² SGA (p=0.923) At least 20 kg/m²	N 1041 736 20) 582 671 2) 975 667 1003	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502 ⊢</li> <li>1749</li> <li>1501</li> <li>1759</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03)
YOutcome(p-for-interaction)Weight (kg) (p=0.233)At least 20 kg/m²Less than 20 kg/m²Length-for-age z-score (p=0.303)At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²BMI z-score (p=0.239)At least 20 kg/m²Less than 20 kg/m²	N 1041 736 975 667 974 664 185) 973	N 1806 1567 1749 1501 1748 1494 1751		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15)	Outcome $(p-for-interaction)$ Low birth weight $(p=0.248)$ At least 20 kg/m²Less than 20 kg/m²Birth weight < 2 kg $(p=0.22)$ At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²SGA $(p=0.923)$ At least 20 kg/m²Less than 20 kg/m²Less than 20 kg/m²	N 1041 736 20) 582 671 2) 975 667 1003	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502 ⊢</li> <li>1749</li> <li>1501</li> <li>1759</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03)
<ul> <li>Outcome <ul> <li>(p-for-interaction)</li> </ul> </li> <li>Weight (kg) (p=0.233) <ul> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul> </li> <li>Length-for-age z-score (p=0.303) <ul> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul> </li> </ul>	N 1041 736 975 667 974 664 185) 973 669	N 1806 1567 1749 1501 1748 1494 1751 1501		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15) 0.13 (0.04, 0.22)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22) At least 20 kg/m² Less than 20 kg/m² Less than 20 kg/m² SGA (p=0.923) At least 20 kg/m² Less than 20 kg/m² Less than 20 kg/m² Less than 20 kg/m²	N 1041 736 582 671 2) 975 667 1003 732	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502 ⊢</li> <li>1749</li> <li>1501</li> <li>1759</li> <li>1564</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03) 0.96 (0.90, 1.03)
<ul> <li>Outcome <ul> <li>(p-for-interaction)</li> </ul> </li> <li>Weight (kg) (p=0.233) <ul> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul> </li> <li>Length-for-age z-score (p=0.303) <ul> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul> </li> <li>BMI z-score (p=0.239) <ul> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul> </li> <li>Head circumference-for-age z-score (p=0.</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>MUAC (p=0.081) <ul> <li>At least 20 kg/m<sup>2</sup></li> </ul> </li> </ul>	N 1041 736 975 667 974 664 185) 973 669 773	N 1806 1567 1749 1501 1748 1494 1751 1501		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15) 0.13 (0.04, 0.22) 0.03 (-0.04, 0.10)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22) At least 20 kg/m² Less than 20 kg/m²	N 1041 736 582 671 2) 975 667 1003 732 973	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502 ⊢</li> <li>1749</li> <li>1501</li> <li>1759</li> <li>1564</li> <li>1751</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03) 0.96 (0.90, 1.03) 0.97 (0.81, 1.17)
<ul> <li>Cutcome</li> <li>(p-for-interaction)</li> <li>Weight (kg) (p=0.233)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>Length-for-age z-score (p=0.303)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>BMI z-score (p=0.239)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul>	N 1041 736 975 667 974 664 185) 973 669 773	N 1806 1567 1749 1501 1748 1494 1751 1501		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15) 0.13 (0.04, 0.22) 0.03 (-0.04, 0.10)	Outcome (p-for-interaction) Low birth weight (p=0.248) At least 20 kg/m² Less than 20 kg/m² Birth weight < 2 kg (p=0.22) At least 20 kg/m² Less than 20 kg/m²	N 1041 736 582 671 2) 975 667 1003 732 973	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502 ⊢</li> <li>1749</li> <li>1501</li> <li>1759</li> <li>1564</li> <li>1751</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03) 0.96 (0.90, 1.03) 0.97 (0.81, 1.17)
<ul> <li>Outcome</li> <li>(p-for-interaction)</li> <li>Weight (kg) (p=0.233)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>Length-for-age z-score (p=0.303)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>BMI z-score (p=0.239)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>Duration (wk) (p=0.840)</li> </ul>	N 1041 736 975 667 974 664 185) 973 669 773 651	N 1806 1567 1749 1501 1748 1494 1751 1501 1548 1488		(95% CI) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15) 0.13 (0.04, 0.22) 0.03 (-0.04, 0.10) 0.11 (0.03, 0.20)	Outcome         (p-for-interaction)         Low birth weight (p=0.248)         At least 20 kg/m²         Less than 20 kg/m²         Birth weight < 2 kg (p=0.22)	N 1041 736 582 671 975 667 1003 732 973 669	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502 ⊢</li> <li>1749</li> <li>1501</li> <li>1759</li> <li>1564</li> <li>1751</li> <li>1501</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03) 0.96 (0.90, 1.03) 0.97 (0.81, 1.17) 0.77 (0.66, 0.90)
<ul> <li>Cutcome</li> <li>(p-for-interaction)</li> <li>Weight (kg) (p=0.233)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>Length-for-age z-score (p=0.303)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> <li>BMI z-score (p=0.239)</li> <li>At least 20 kg/m<sup>2</sup></li> <li>Less than 20 kg/m<sup>2</sup></li> </ul>	N 1041 736 975 667 974 664 185) 973 669 773 651 1062	N 1806 1567 1749 1501 1748 1494 1751 1501 1548 1488 1820		(95% Cl) 0.04 (0.02, 0.07) 0.06 (0.03, 0.09) 0.10 (0.02, 0.18) 0.14 (0.05, 0.23) 0.09 (0.01, 0.16) 0.13 (0.04, 0.22) 0.08 (0.01, 0.15) 0.13 (0.04, 0.22) 0.03 (-0.04, 0.10) 0.11 (0.03, 0.20) 0.11 (-0.05, 0.27)	Outcome (p-for-interaction) Low birth weight $(p=0.248)$ At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Birth weight < 2 kg $(p=0.22)$ At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Low HCAZ $(p=0.049)$ At least 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup> Less than 20 kg/m <sup>2</sup>	N 1041 736 582 671 975 667 1003 732 973 669 887	<ul> <li>N</li> <li>1806</li> <li>1567</li> <li>1357</li> <li>1357</li> <li>1502</li> <li>↓</li> <li>1749</li> <li>1501</li> <li>1759</li> <li>1564</li> <li>1751</li> <li>1501</li> <li>1653</li> </ul>		(95% Cl) 0.93 (0.80, 1.08) 0.87 (0.76, 0.98) - 1.08 (0.66, 1.78) 0.69 (0.46, 1.02) 0.89 (0.75, 1.06) 0.80 (0.69, 0.93) 0.95 (0.87, 1.03) 0.96 (0.90, 1.03) 0.97 (0.81, 1.17) 0.77 (0.66, 0.90) 0.92 (0.71, 1.19)

			Difference	-
		-0.4	0	0.4
Less than 20 kg/m <sup>2</sup>	755	1588	<b>₽</b>	<b>H</b> 0.12 (-0.08, 0.31)
At least 20 kg/m <sup>2</sup>	1062	1820	<b>⊢</b>	0.11 (-0.05, 0.27)
Duration (wk) (p=0.840)				
Less than 20 kg/m <sup>2</sup>	651	1488	┟──■──┤	0.11 (0.03, 0.20)
At least 20 kg/m²	773	1548	┝┼┳╌┥	0.03 (-0.04, 0.10)
MUAC (p=0.081)				
Less than 20 kg/m <sup>2</sup>	669	1501	┝╌┲╌┤	0.13 (0.04, 0.22)
At least 20 kg/m²	973	1751	┝╌═─┤	0.08 (0.01, 0.15)
• "	•			

Favors IFA/SOC Favors SQ-LNS

#### E) Maternal age

Outcome	SQ-LNS	IFA/SC	C			Mean difference
(p-for-interaction)	Ν	Ν				(95% CI)
Weight (kg) (p=0.257)						
At least 25 y	723	1173			┝╼┥	0.07 (0.03, 0.11)
Less than 25 y	1092	2285			⊦≡⊣	0.04 (0.01, 0.07)
Length-for-age z-score (p=0.699)						
At least 25 y	668	1113			┝──■──┤	0.13 (0.04, 0.23)
Less than 25 y	1012	2221			<b>├──</b> ■──┤	0.09 (0.01, 0.17)
BMI z-score (p=0.245)						
At least 25 y	667	1111			┝──■──┤	0.14 (0.05, 0.24)
Less than 25 y	1009	2215			┝──■──┤	0.08 (0.00, 0.15)
Head circumference-for-age z-score (p=0.395)						
At least 25 y	668	1115			∎	0.15 (0.06, 0.25)
Less than 25 y	1012	2221			ŀ <b></b> ■ł	0.07 (-0.01, 0.15)
MUAC (p=0.621)						
At least 25 y	582	1012			┝──■──┤	0.10 (0.01, 0.18)
Less than 25 y	879	2108			ŀ <b>_</b> ■ł	0.07 (-0.01, 0.14)
Duration (wk) (p=0.020)						
At least 25 y	744	1189		<b> </b>		-0.06 (-0.27, 0.15)
Less than 25 y	1111	2304			⊢∎	0.23 (0.06, 0.39)
			-0.4		0	0.4
			-0.4		Difference	U.T
			Favors	IFA/SOC	Favors SQ-I	_NS

F) Maternal age

Outcome		IFA/SOC		Relative risk
(p-for-interaction)	Ν	Ν		(95% CI)
Low birth weight (p=0.481)				
At least 25 y	723	1173	⊧∎ł	0.85 (0.70, 1.03)
Less than 25 y	1092	2285	⊦ <del>∎</del> ∤	0.92 (0.82, 1.03)
Birth weight < 2 kg (p=0.022)				
At least 25 y	633	1070	<b>⊢∎</b>	<b>H</b> 1.26 (0.77, 2.08)
Less than 25 y	959	2172	⊢	0.64 (0.47, 0.86)
Newborn stunting (p=0.343)				
At least 25 y	668	1113	├──■┤──┤	0.91 (0.72, 1.16)
Less than 25 y	1012	2221	┝━━━┥	0.80 (0.70, 0.92)
SGA (p=0.052)				
At least 25 y	705	1151	┝╌═╌┥	0.87 (0.77, 0.97)
Less than 25 y	1068	2257	F <b>₩</b> -1	1.00 (0.94, 1.06)
Low HCAZ (p=0.920)				
At least 25 y	668	1115	┝───■──┤┥	0.84 (0.66, 1.06)
Less than 25 y	1012	2221	<b>⊢_</b> ∎ł	0.85 (0.71, 1.01)
Preterm birth (p=0.236)				
At least 25 y	744	1189	⊢─────────────────	1.07 (0.82, 1.39)
Less than 25 y	1111	2304	⊢■┤	0.87 (0.71, 1.06)
			0.50 1.0 2.0 Ratio	00
			Favors SQ-LNS Favors IFA/SO	С

Favors SQ-LNS

Ratio

Favors IFA/SOC

Maternal inflammation H)

G) Maternal inflammation

1352

643

0.95 (0.86, 1.05)

Outcome	SQ-LNS	IFA/SOC		Mean difference
(p-for-interaction)	Ν	Ν		(95% CI)
Weight (kg) (p=0.118)				
Non-inflamed	816	772	┠═┥	0.03 (0.00, 0.07)
Inflamed	401	343	┝╼╾┥	0.09 (0.03, 0.16)
Length-for-age z-score (p=0.280)				
Non-inflamed	749	704	┝┼╼╌╢	0.06 (-0.04, 0.16)
Inflamed	337	292	┞───■───┤	0.21 (0.03, 0.38)
BMI z-score (p=0.242)				
Non-inflamed	746	702	┝─■─┤	0.09 (-0.01, 0.20)
Inflamed	336	286	<b>├──</b> ■──┤	0.20 (0.02, 0.37)
Head circumference-for-age z-score (p	o=0.607)			
Non-inflamed	747	705	┝──■──┤	0.11 (0.00, 0.21)
medRXV preprint doi: https://doi.org/10.1101/2024.05.17.2 (which was not certified by peer review) is the author MUAC (p=0.189)	24307546; this version posted M /funder, who has granted medR: e under a CC-BY 4.0 Internation	ay 17, 2024. The copyright l xiv a license to display the p al license .	holder for this preprint reprint in perpetuity.	0.20 (0.01, 0.38)
Non-inflamed	749	705	⊦ <b>⊢≡</b> −1	0.06 (-0.03, 0.14)
Inflamed	339	292	<b>⊢</b> _∎{	0.19 (0.04, 0.33)
Duration (wk) (p=0.090)				
Non-inflamed	858	805	<b>⊢</b> ∎1	0.02 (-0.18, 0.22)
Inflamed	430	382	⊢∎	<b>——</b> 0.39 (0.06, 0.72)
I) Food insecurity		-0.4 Favors IFA/	0 0.4 Difference /SOC Favors SQ-LNS	
Outcome	SQ-LNS	IFA/SOC		Mean difference
(p-for-interaction)	Ν	Ν		(95% CI)
Weight (kg) (p=0.103)				. ,
Mild to secure	945	1884	┝═┤	0.03 (0.00, 0.06)
Moderate to severe	643	1352	┝╼┤	0.07 (0.03, 0.11)
Length-for-age z-score (p=0.047)				
Mild to secure	897	1844	<b>⊢</b> ∎1	0.06 (-0.02, 0.13)
Moderate to severe	556	1271	■	0.17 (0.08, 0.27)
BMI z-score (p=0.249)				
Mild to secure	897	1841	<b>⊨</b> 1	0.07 (-0.01, 0.15)
Moderate to severe	552	1266	⊦∎1	0.13 (0.02, 0.24)
Head circumference-for-age z-score (p	o=0.144)			
Mild to secure	898	1844	⊦ <b>⊢</b> ∎−−1	0.05 (-0.03, 0.12)

555

Moderate to severe


1273

Outcome	SQ-LNS	IFA/SOC	Relative risk
(p-for-interaction)	Ν	Ν	(95% CI)
Low birth weight (p=0.140)			
Non-inflamed	816		0.89 (0.76, 1.05)
Inflamed	401	343	0.67 (0.49, 0.92)
Birth weight < 2 kg (p=0.808)			
Non-inflamed	816	772	0.91 (0.55, 1.50)
Inflamed	401	343 -	0.85 (0.36, 2.01)
Newborn stunting (p=0.189)			
Non-inflamed	749	704	0.91 (0.73, 1.12)
Inflamed	337	292	0.69 (0.49, 0.97)
SGA (p=0.963)			
Non-inflamed	816		0.95 (0.85, 1.07)
Inflamed	401	343	0.94 (0.77, 1.15)
Low HCAZ (p=0.095)			
Non-inflamed	747	705	0.91 (0.74, 1.11)
Inflamed	338	292	0.60 (0.41, 0.89)
Preterm birth (p=0.284)			
Non-inflamed	858	805	1.09 (0.82, 1.46)
Inflamed	430	382	0.80 (0.55, 1.15)
		0.50 1.0	2.00
		Ratio	
		Favors SQ-LNS	Favors IFA/SOC
Food insecurity		Favors SQ-LNS	Favors IFA/SOC
Food insecurity Outcome	SQ-LNS	Favors SQ-LNS	Favors IFA/SOC Relative risk
	SQ-LNS N		
Outcome		IFA/SOC	Relative risk
Outcome (p-for-interaction)		IFA/SOC	Relative risk
Outcome (p-for-interaction) Low birth weight (p=0.176)	N	IFA/SOC N	Relative risk (95% Cl)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure	<b>N</b> 945	IFA/SOC N 1884 <b>⊢ ■ −1</b>	<b>Relative risk</b> ( <b>95% CI)</b> 0.96 (0.84, 1.10)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe	<b>N</b> 945	IFA/SOC N 1884 <b>⊢ ■ −1</b>	<b>Relative risk</b> ( <b>95% CI)</b> 0.96 (0.84, 1.10)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe Birth weight < 2 kg (p=0.189)	<b>N</b> 945 643	IFA/SOC N 1884	<b>Relative risk</b> ( <b>95% CI</b> ) 0.96 (0.84, 1.10) 0.84 (0.71, 0.99)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe Birth weight < 2 kg (p=0.189) Mild to secure	<b>N</b> 945 643 945	IFA/SOC N 1884	<b>Relative risk</b> ( <b>95% CI</b> ) 0.96 (0.84, 1.10) 0.84 (0.71, 0.99) 0.90 (0.66, 1.23)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe Birth weight < 2 kg (p=0.189) Mild to secure Moderate to severe	<b>N</b> 945 643 945	IFA/SOC N 1884	<b>Relative risk</b> ( <b>95% CI</b> ) 0.96 (0.84, 1.10) 0.84 (0.71, 0.99) 0.90 (0.66, 1.23)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe Birth weight < 2 kg (p=0.189) Mild to secure Moderate to severe Newborn stunting (p=0.052)	N 945 643 945 643	IFA/SOC N 1884	<b>Relative risk</b> (95% Cl) 0.96 (0.84, 1.10) 0.84 (0.71, 0.99) 0.90 (0.66, 1.23) 0.63 (0.41, 0.99)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe Birth weight < 2 kg (p=0.189) Mild to secure Moderate to severe Newborn stunting (p=0.052) Mild to secure	N 945 643 945 643 897	IFA/SOC N 1884	<b>Relative risk</b> (95% Cl) 0.96 (0.84, 1.10) 0.84 (0.71, 0.99) 0.90 (0.66, 1.23) 0.63 (0.41, 0.99) 0.93 (0.80, 1.08)
Outcome (p-for-interaction) Low birth weight (p=0.176) Mild to secure Moderate to severe Birth weight < 2 kg (p=0.189) Mild to secure Moderate to severe Newborn stunting (p=0.052) Mild to secure Moderate to severe	N 945 643 945 643 897	IFA/SOC N 1884	<b>Relative risk</b> (95% Cl) 0.96 (0.84, 1.10) 0.84 (0.71, 0.99) 0.90 (0.66, 1.23) 0.63 (0.41, 0.99) 0.93 (0.80, 1.08)

┝╼═┼┨

J)

Moderate to severe



0.16 (0.05, 0.28)


┣───╋─

# Anthropometric outcomes at 6 mo stratified by infant sex, SQ-LNS vs IFA/SOC


B)

Outcome	SQ-LNS	IFA/SOC		Mean difference	Outco
(p-for-interaction)	Ν	Ν		(95% CI)	(p-
Weight-for-age z-score (p=0.005)					Under
Male	849	1661		-0.05 (-0.15, 0.06)	Ма
					Fe
Female	867	1652	│ <b>├──₩</b> ──┤	0.12 (0.03, 0.20)	Stunte
Length-for-age z-score (p=0.008)					Ма
Male	849	1660	} <b>⊢_</b> ∎	-0.02 (-0.11, 0.08)	Fe
Female	868	1655	⊢_∎{	0.12 (0.04, 0.20)	Waste
					Ma
Weight-for-length z-score (p=0.075)					Fe
Male	849	1660	┠──╋┤┤	-0.06 (-0.15, 0.04)	Low H
Female	867	1652	┞┼╼╾╌┥	0.05 (-0.04, 0.14)	Ма
Head circumference-for-age z-score (p=0.035	5)				Fe
Male	849	1659	┝──╋─┤	-0.05 (-0.13, 0.02)	Low N
Female	868	1652		0.06 (-0.02, 0.14)	Ма
	000	1032	· - ·	0.00 (-0.02, 0.14)	Fe
MUAC-for-age z-score (p=0.025)					Acute
Male	747	1550	<b>⊢</b> ∎ ┤	-0.07 (-0.16, 0.03)	Ma
Female	751	1552	<b>⊢</b> ∎1	0.07 (-0.03, 0.16)	Fe
		-0.4	0 Difference	0.4	
		Favors		SQ-LNS	

A)



### Birth weight




medRxiv preprint doi: https://doi.org/10.1101/2024.05.17.24307546; this version posted May 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

B)

A)

### Newborn LAZ



#### **Newborn HCZ**

SQ-LNS MMS	MD	Fixed Random

